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Abstract
The Retinoblastoma Gene (Rb) plays a pivotal role in the control of cell
division and cancer development. Loss of normal Rb function is thought to be a
prerequisite for the development of all cancers. The observation that viral hepatitis, a
major risk factor for the development of liver cancer, may modulate the function of
Rb, suggests a role for Rb in the early stages of hepatocarcinogenesis.
It is not possible to model Rb loss in vivo using conventional knockout mice
as Rb deletion is embryonic lethal. Instead, it was necessary to employ Cre Lox
technology in order to develop a conditional knockout system. Using an adenoviral
delivery system, liver-specific deletion of the floxed Rb gene could be achieved at
levels proportional to the viral titre used.
To determine the role ofRb in the regulation of hepatocyte replication, two
models of liver regeneration were developed. The first involved the use of the liver-
specific toxin, carbon tetrachloride, to cause necrosis. The second involved
performing a partial hepatectomy (PH) - surgical resection of approximately 2/3 of
the murine liver. When liver regeneration following either hepatectomy or necrosis
occurred following Rb loss, the result was deregulated hepatocyte division, with
acceleration of hepatocyte proliferation. Loss of Rb also reduced the normal process
of polyploidisation that usually occurs during regeneration.
To determine the role ofRb in liver cancer, a model of hepatocarcinogenesis
was developed using the DNA damaging agent, diethylnitrosamine, together with
protracted administration of carbon tetrachloride to produce sustained necrosis and
regeneration. Following this treatment, loss of Rb was associated with increased
levels of apoptosis and the development of preneoplastic foci that are characteristic
of the early stages of hepatocarcinogenesis. These foci showed increased staining for
markers ofproliferation as compared to surrounding liver tissue. Quantification of
foci demonstrated Rb loss was associated with an increase in the frequency, size, and
total area of preneoplastic tissue.
Considered together, these results demonstrate an important role for Rb in the
regulation of liver regeneration and polyploidisation. When Rb loss occurs on a
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background ofDNA damage and sustained inflammation, analogous to chronic liver
disease, there is an acceleration of the preneoplastic phase of hepatocarcinogenesis
suggesting loss ofRb may be a critical factor in the development of liver cancer.
PhD - The University ofEdinburgh - 2006 8
Abbreviations
AFB aflatoxin B
ARF alternative reading frame
ATM ataxia telangiectasia-mutated protein
ATR ataxia telangiectasia - related
Bcl-2 B-cell lymphoma
BrdU 5-bromodeoxy-uridine
c-abl abelson murine leukemia oncogene 1
CAH chronic active hepatitis
CAR Cocksackie Adeno Receptor
cdk cyclin dependent kinase
CIP/KIP cdk inhibitory protein/kinase-inhibitory protein
CKI cdk inhibitor
CNS central nervous system
Cre cyclization recombinase enzyme






E2F early region factor 2
EAF enzyme altered foci
EGF epidermal growth factor
ERCC excision repair cross-complementing rodent repair deficiency complementation group 1
FAH focus of altered hepatocytes
floxed flanked by loxP sites
HAT histone acetylase
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HBX hepatitis B X protein
HCC Hepatocellular carcinoma
HEC1 highly conserved in cancer 1
HDM2 human double minute clone 2 oncoprotein
HCV hepatitis C virus
HDAC histone deacetylase
IGF insulin like growth factor
IL interleukin
INK4 inhibitor of kinase 4
LEC long-Evans rat with a cinnamon-like color
LOH loss of heterozygosity
LoxP locus of crossover of P1
LPS lipopolysaccharide
MAPK mitogen-activated protein kinase
MDM2 mouse double minute clone 2 oncoprotein
MEFs mouse embryonic fibroblasts
mRNA messenger ribonucleic acid
MSi micro satellite instability
NES nuclear export signal
NF-kB nuclear factor kB
PhD - The University of Edinburgh - 2006 9
NLS nuclear localisation signal
NS5A hepatitis C virus nonstructural 5A
PBS phosphate buffered saline
PCNA proliferating cell nuclear antigen
PCR polymerase chain reaction
pfu plaque forming units
PH partial hepatectomy
PNS peripheral nervous system
pRb retinoblastoma protein
Rb retinoblastoma gene
RFLP restriction fraction length polymorphisms
RNA ribonucleic acid
STAT3 signal transducer and activator of transcription 3
Skp2 S-phase kinase-associated protein 2 (p45)
TGFa transforming growth factor a
TGF(3 transforming growth factor IS
TNFR tumour necrosis factor receptor
TNFa tumour necrosis factor
PhD - The University of Edinburgh - 2006 10
Chapter 1 Introduction
Cell cycle control is integral to the strict regulation of hepatocyte proliferation seen
in liver regeneration and during the response of the liver to injury. By extension, the
failure of such strict control in an environment of chronic repair and proliferation
will have clear implications for the development of populations of cells which show
deregulated cell cycling, a prerequisite to the development of cancer.
This chapter aims to review current understanding of the processes that control the
normal responses to injury which occur during liver regeneration and repair, in
relation to how such control is disrupted in the process of hepatocarcinogenesis.
Section A
An overview of the pRb pathway
A Retinoblastoma is a rare tumour which presents in childhood as a consequence of
an inherited mutation of the Retinoblastoma Gene (Rb). Development of the tumour
is associated with the loss of the second allele. Rb was the first tumour suppressor
gene to be identified and cloned (Friend et al. 1986). The pattern of inheritance, and
development ofRetinoblastoma, gave rise to the "two hit" theory of tumour
suppressor inactivation as a mechanism for the development of cancer (Knudson, Jr.
1971). Subsequent investigation demonstrated that Rb was frequently lost in other
more common cancers occurring in adulthood, including lung cancer (Harbour et al.
1988) and osteosarcoma (Friend et al. 1986). Further examination of the function of
Rb demonstrated a key role in cell cycle regulation, such that loss of Rb function is
now seen as an essential step in the development of cancer (Hahn et al.
2002;Hanahan et al. 2000;Sellers et al. 1997;Sherr 1996)
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pRb is a member of the pocket protein family. Fitting with a fundamental role in the
development of human cancer, the functions of pRb, and fellow members of the
pocket protein family, encompass the integration ofmany regulatory cell cycle
pathways including those of cell survival, replication and death.
Structure of the Retinoblastoma Protein
The retinoblastoma protein (pRb) is a large nuclear protein (928 amino acids with a
molecular weight of 110 kD and has a long half-life (Chen et al. 1989). pRb is
ubiquitously expressed in all mammalian tissues (Lee et al. 1987). The protein has
three distinctive domains: an N terminal domain, a C terminal domain, and a central
A and B region. The A and B regions interact to form the characteristic A/B pocket.
This pocket contains a number of important protein binding domains, including
binding sites for the early region factor 2 (E2F) group of transcription factors (Lee et
al. 1998). pRb lacks a DNA binding domain, but instead is attached to promoters via
transcription factors such as the E2Fs. The importance of the pocket region was first
demonstrated through its association with DNA virus oncoproteins, which were
shown to bring about cell transformation in vitro by binding to the pocket region, and
hence, inactivating pRb (Dyson et al. 1989;Hu et al. 1990). It is the A/B pocket that
determines the biological activities of the protein, and correspondingly it is this
region of the protein that is most frequently mutated in human tumours (Hu et al.
1990). The C terminal domain of pRb interacts with a number of cell cycle related
proteins, including MDM2 (mouse double minute clone 2 oncoprotein), p53, and c-
abl (abelson murine leukemia oncogene 1) (Welch et al. 1993;Xiao et al. 1995). In
addition, the C terminal domain has a number of cdk phosphorylation sites. The
function of the N terminal remains unclear. The pocket region is the common feature
of the pocket protein family which, in addition to pRb, includes the proteins pi 07
and pi30.
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p107 and p130, fellow members of the pocket protein family
Although all three members of the pocket protein family share the same pocket
protein region, pl07 and pl30 have more in common with each other than with pRb.
pi07 and pi 30 have different binding partners and bind different members of the
E2F family of transcription factors (Figure 1) than pRb. Whereas pRb is expressed in
both proliferating and non proliferating cells, pi07 is expressed at a higher level in
proliferating cells than quiescent cells, and pi30 is expressed at a higher level in
quiescent cells compared to proliferating cells. Thus, during the transition from
quiescence to proliferation, the levels of pRb remain relatively stable, whilst there is
a rapid rise in levels ofpi 07, and a corresponding decrease in the levels ofpi 30
(Figure 2, next page). (Classon et al. 2001;Grana et al. 1998). In terms of function,
Rb, pi07, and pi30 can all arrest cells in G1 when over-expressed (Claudio et al.
1994;Zhu et al. 1993). There is increasing acknowledgement that a degree of
functional over-lap exists in the tumour suppressor activity of the pocket proteins.
However, they also exhibit varying levels of specificity during different phases of the
cell cycle.
Activator E2Fs Represor E2Fs
Figure 1 The pocket proteins have various binding affinities for different members of
the E2F family.
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GO G1 S
Figure 2 Schematic representation of the change in expression of pocket proteins
during progression of the cell cycle.
Regulation of the Pocket Proteins
The activity of the pocket proteins is regulated by a number of different mechanisms
which include:
• Phosphorylation by cyclin dependent kinases (CDK) during cell cycle
progression
• Genetic inactivation as occurs in the development of cancers
• Functional inactivation by viral oncoproteins
• Caspase degradation during the process of apoptosis(Chau et al. 2003)
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Pocket Protein Regulation during the cell cycle
The observation that multiple, differently phosphorylated forms of pRb existed in
vivo, together with its long half-life; suggested Rb was predominantly regulated by
post-translational phosphorylation. The phosphorylation of pRb and that of the other
pocket proteins is now known to vary in a cell cycle-dependent manner
(Beijersbergen et al. 1996;Grana et al. 1998). In GO, pRb is predominantly
hypophosphorylated, whilst in Gl, S, G2 and M phases of the cell cycle it is
hyperphosphorylated. The hypophosphorylated form ofRb is the active form;
therefore, phosphorylation of pRb, which occurs early in cell cycle progression,
renders it inactive. Injection of hypophosphorylated Rb into cells brings about cell
cycle arrest (Goodrich et al. 1991), and phosphorylation of pRb brings about ectopic
cell cycle entry. Phosphorylation ofRb increases following serum stimulation, and
decreases in response to anti-proliferative cytokines, such as transforming growth
factor p, (TGFB) (Laiho et al. 1990). Phosphorylation of pRb causes a
conformational change in the pocket region which results in reduced binding affinity
for E2F transcription factors (Harbour et al. 1999). pRb remains inactivated until the
end ofmitosis when a combination of decreasing protein kinase activity, and
increasing protein phosphatase activity, bring about the dephosphorylation and
reactivation of pRb. (Yan et al. 1999)
An established, simplified working model for the function of pRb, proposes that in
quiescence, active, hypo-phosphorylated pocket proteins prevent cell cycle entry.
Suppression of cell cycle entry occurs predominantly through interaction with the
E2F group of transcription factors. The repressive activity of pRb is determined by
its phosphorylation status, which is dependent on the balance between protein
kinases and protein kinase inhibitors. The balance of kinase activity is in turn
determined by pro- and anti-proliferative signals. Mitogenic stimulation increases the
activity of kinases, predominantly CDKs, and reduces the activity of cyclin kinase
inhibitors (CKIs). Hence, the pocket proteins are phosphorylated and deactivated.
Deactivation of the pocket proteins abrogates their repressive effects on proliferation
PhD - The University of Edinburgh - 2006 15
by releasing the E2F transcription factors that transcribe a host of genes required for
cell cycle progression (Muller et al. 2001). Transcription of such genes therefore
occurs and the cell consequently moves into S phase.
Regulation of pRb activity through phosphorylation by cyclin dependent kinases
Hyper-phosphorylation of pRb occurs at multiple sites on the protein and is mediated
by the following cdks in a sequential fashion during progression of the cell cycle.
• Cyclin D-cdk4/6 in early G1
• Cyclin E-cdk2 at the end ofG1
• Cyclin A-cdk2 during S phase.
Mitogenic signalling increases cyclin D levels (Matsushime et al. 1991), increases
the synthesis and stability of cyclin D-dependent cdks, and reduces the association of
cdks with cyclin kinase inhibitors (Sherr and Roberts 1999). Cyclin D1 has been
shown to be required for cell cycle progression through Gl(Baldin et al. 1993). The
resulting phosphorylation of pRb by Cyclin D-cdk4/6 complexes increases E2F
activity (Harbour et al. 1999). E2F then increases the activity ofCyclins E and A,
which contribute further to the phosphorylation of pRb during S phase until the point
of cell division at mitosis (reviewed (Sherr 2000). Ectopic expression of Cyclins D, E
or A is able to abrogate the repressive effect of functional pRb.(Horton et al. 1995).
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Regulation of pRb activity through inhibition of phosphorylation by Cyclin
Kinase Inhibitors
The actions of cdks are opposed by two families of cdk inhibitors (CKIs), the
CIP/KIP family, and the INK4 family.
1.The CIP/KIP family
The first family of CKIs is known as the Cdk-Inhibitory Protein Kinase -Inhibitory
Protein family (CIP/KIP), and includes P27KIP1, p21WAF1/CIP1 and p57 KIP2.
CIP/KIP proteins interact specifically with both cyclins and cdks. The most
functionally important CIP/KIP is p21. p21 was first identified as a senescence-
inducing protein (el Deiry et al. 1994), and is now known to mediate repression of
cell cycle progression by two main mechanisms. Firstly, it associates with, and
specifically inhibits, Cyclin E- and Cyclin A-dependent kinases, therefore
maintaining pRb in the hypophosphorylated state (reviewed (Gartel et al. 2005)).
During Gl, increasing levels of Cyclin D-cdk 4/6 help to sequester p21 from Cyclin
E-CDK2, thus increasing its activity late in Gl. Secondly, p21 has a direct inhibitory
effect on cell cycle progression through its action on the DNA synthetic machinery,
including proliferating cell nuclear antigen (PCNA) (Waga et al. 1994).
The activity of the CIP/KIP family is regulated at a number of different levels.
TGFfl, which generally inhibits cell cycle progression, increases levels of both p21
and pi 5 ( a member of the INK4 family) (Reynisdottir et al. 1995). DNA damage
stabilises the tumour suppressor protein p53 which increases levels of p21, leading to
pRb inactivation and cell cycle arrest (Agarwal et al. 1995)
2.The INK4 family
The second family ofCKIs is the inhibitor of cdk4 family (INK4), whose members
include pi6 INK4a, pi5 INK4b, pi8 INK4c and pl9 INK4d. Each member
specifically binds and inhibits Cyclin D-dependent kinases by blocking the kinase
PhD - The University of Edinburgh - 2006 17
active site, thus preventing association with cyclins. In the absence ofpi 6 protein,
cdk4 binds Cyclin D and phosphorylates pRb, therefore stimulating entry into S
phase.(reviewed (Roussel 1999). In contrast to the CIP/KIP family, mutations such
as methylation and homozygous deletion in the INK4 family, particularly pi6
INK4a, are commonly implicated in the aetiology of human cancer (Ortega et al.
2002).
pi6 INK4a shares a chromosomal locus with pl4 alternative reading frame (pi4
ARF); equivalent to the mouse protein, pi9 ARF. pl4ARF acts as a tumour
suppressor through specific activation of the p53 pathway. pl4ARF stabilises p53 by
inhibiting mouse double minute clone 2 oncoprotein (MDM2), which is the ubiquitin
ligase responsible for the degradation of p53. pl4ARF acts to sense the mitogenic
current through the cell and is activated in response to oncogenic signals, such as c-
myc and ras, leading to p53 stabilisation (reviewed (Serrano et al. 1996;Serrano
2000). Deletions of the INK4a/ARF locus result in the loss of two distinct tumour
suppressor activities, and such deletions have been identified in a variety of human
cancers (Ruas et al. 1998)
Deregulation of pocket protein function through viral inactivation in
carcinogenesis
The normal regulation, and hence activity, of pRb is disrupted in a number of
pathological states. Viral oncoproteins inhibit the binding of pRb to E2F (Chellappan
et al. 1992). Study of the interaction between viral oncoproteins and pRb aided
elucidation of the oncogenic mechanisms of such tumour suppressor proteins, and
provided important observations which identified pRb as a key regulator of the cell
cycle.
The deregulation of pRb in oncogenesis occurs through a number of different
mechanisms that may involve both the loss of expression, or function, of pRb itself
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(through deletion (Knudson, Jr. et al. 1976), mutation (Horowitz et al. 1989) or
methylation (Ohtani-Fujita et al. 1993). The function of Rb can also be affected by
either the loss of function, or gain of function, of other components of the Rb
pathway, such as the cyclin kinase inhibitors or cyclins.
Loss of pRb function is considered to be an obligatory step in the development of
cancer (Hanahan et al. 2000), though there is considerable variation between tumours
as to which is the predominant dysfunctional element of the Rb pathway. Loss of one
element of the pathway tends to be predominant in any particular tumour, mutually
excluding the loss of another element. For example, the loss of function of pl6INK4a
can be demonstrated throughout the spectrum of human tumours, but, whereas loss
of function ofpl6INK4a occurs in the majority of pancreatic cancers, (Rozenblum et
al. 1997), it is an uncommon finding in small lung cancers.(Wistuba et al. 2001).
Similarly, over expression of Cyclin D1 is very common in Mantle cell lymphoma
(Dreyling et al. 1997), but is unusual in small cell lung cancer. The spectrum of
perturbations which occur in the Rb/E2F pathway during the development of liver
cancer are discussed in Section D "Liver Cancer"of this chapter.
Rb is regulated by apoptotic pathways
In addition to regulation through phosphorylation, pRb is also regulated as a
consequence of activation of the apoptotic cascade and is degraded by caspases.
(Chau et al. 2003)
In vivo models of Rb Loss
Examination of the consequences ofRb loss in vivo has helped elucidate the role of
Rb in development, cell cycle regulation, and tumorigenesis (reviewed (Classon et al.
2002). In vivo models have employed murine knockouts, both conventional and
conditional. Drosophila melanogasta have also proved a powerful experimental tool
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in the study of Rb function, particularly because there are a smaller number of both
pocket proteins and E2F family members in this species (Stevaux et al. 2002). Such
knockouts have demonstrated the importance of Rb in the development of the whole
organism, as well as in the development of tumours in a number of different organs.
In addition to demonstrating that Rb loss may be a critical event in the development
of various tumours, such studies have also demonstrated the differences that exist
between humans and mice, particularly regarding functional redundancy in the
pocket proteins, which is apparent in mice but not humans.
Rb appears to be essential for normal intrauterine development. Homozygous Rb null
mice die in mid gestation (Clarke et al. 1992;Jacks et al. 1992). The reasons for this
are not entirely clear. Initially, it was assumed Rb loss was directly responsible for
the deranged phenotype seen in these ill fated embryos, which died at 13/4 days
exhibiting gross defects in the haematopoietic and nervous systems, as well as
developmental abnormalities in the lens and skeletal muscle. Since then, it has been
suggested that both the abnormalities and intrauterine death may be secondary to
placental abnormalities, for which Rb loss is directly responsible (Wu et al. 2003).
Examination of Rb null embryos suggested a number of biological functions that
might be regulated by Rb. These include ectopic cell cycle activity and increases in
the level of apoptosis. The role of Rb in apoptosis is discussed later in this chapter.
Germ line Rb loss is associated with increased E2F activity (Almasan et al. 1995).
The phenotype resulting from Rb loss may, at least in part, be mediated through
deregulated E2F activity. Evidence for this suggestion comes from the observation
that the phenotype typical of Rb loss - one of increased apoptosis and deregulated
proliferation, can be partly relieved by concomitant E2F deletion (Maehara et al.
2005;Yamasaki et al. 1998). Interestingly, in Rb null chimeras where Rb null cells
contribute to all tissues, the mice survive and exhibit only very mild phenotypic
alterations (Williams et al. 1994c) suggesting Rb may have an additional non
autonomous role in development (Whyatt et al. 2002).
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Children with Rb haplo-insufficency not only develop Retinoblastoma, but are at a
much higher risk of developing further tumours in later life, particularly bone and
soft tissue sarcomas and melanomas (Moll et al. 1997). Similarly, mice which have
been engineered to carry a single germ line mutation of Rb develop a spectrum of
tumours with complete penetrance. In these mice, tumours tend to be in the pituitary
and thyroid glands, and exhibit loss of heterozygosity at the Rb locus (Harrison et al.
1995;Jacks 1996). However, Retinoblastoma does not develop in mice heterozygous
for Rb, nor does Retinoblastoma develop in bi-allelic conditional knockouts in
mouse photoreceptor cells (Vooijs et al. 2002). The development of Retinoblastoma
in the mouse requires the additional loss of pi 07 (Robanus-Maandag et al. 1998).
This functional overlap between Rb and pi07 in the mouse has also been
demonstrated in the phenotype of deregulated cell cycling following Rb loss. In
mouse embryonic fibroblasts (MEFs), conditional acute Rb deletion leads to
deregulated cell cycling, but when Rb loss is engineered at the germ line level, there
is a compensatory increase in pi 07 and alleviation of deregulated phenotype (Sage et
al. 2003). Similar findings have been demonstrated in a conditional liver-specific Rb
knockout (Mayhew et al. 2005). In addition, mice with a conditional Rb deletion in
combination with pi07 loss are particularly susceptible to cancer (Dannenberg et al.
2004). This functional overlap between Rb and pi07 in mice may be because pi07 is
a downstream transcriptional target of E2F (Muller et al. 2001) i.e. loss of Rb leads
to increased E2F activity and pi07 is up regulated. In humans, Rb deletion does not
result in increased pi07 activity. For example, pi07 activity is not increased
following Rb loss in human retinal progenitor cells (Dyer et al. 2005). Such a
functional overlap occurring in mice, but not humans may explain why inactivation
ofRb alone is sufficient for retinoblastoma development in humans but not mice.
Mice deficient in pi07 or pi30 develop normally and exhibit only very mild
phenotypic alterations which tend to be strain-dependent (Cobrinik et al. 1996;Lee et
al. 1996b;Lee et al. 1996a). Double knockout of pi 07 and pi 30 results in some
developmental abnormalities, including abnormal bone development suggesting a
functional overlap in the contribution of pl07 and pi30 to development (Cobrinik et
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al. 1996). Mice homozygous or heterozygous for deletions of either pi 07 or pi 30, or
both, do not develop tumours. Similarly, mutation ofpi 07 or pi 30 is a rare event in
human cancer (Mulligan et al. 1998)
E2F family of transcription factors
Rb mediates its repressive effects on cell cycle proliferation predominantly through
its interactions with the E2F family of transcription factors. The E2F family are
responsible for the transcription of a host of genes required for cell proliferation,
including those required for DNA synthesis (such as PCNA), for cdk activity, and for
recognition and utilization of replication origins (reviewed (Dyson 1998).
E2F was first demonstrated as a biochemical factor through which adenoviral
infection could bring about expression of cell cycle genes (Nevins 1992). It was
subsequently demonstrated that this transcriptional activity was restrained by the
binding of Rb to E2F, and that the viral oncoprotein ElA could disrupt this
association, thereby causing DNA synthesis and potentially contributing to
oncogenic transformation (reviewed (Nevins 1992).
Early studies demonstrated that hypophosphorylated pRb binds to, and inhibits, the
E2F transactivation domain, thus preventing cell cycle progression (reviewed (Berk
1986). Since then it has been demonstrated that, in addition to the regulation of
replication, the E2F family of transcription factors exhibit a wide range of functions
with different family members playing different, often contrasting roles, depending
on the context (Attwooll et al. 2004). In addition to their predominant role in cell
proliferation and differentiation, E2F family members also act on a wide and diverse
range of transcriptional targets in order to regulate a number of different biological
processes including apoptosis, development, and tumorigenesis (reviewed (Cam et
al. 2003;DeGregori 2002).
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Mammalian E2F Family
Eight members of the mammalian E2F family have so far been identified and these
interact variably with the pocket proteins. Members of E2F family form functional
heterodimers with the dimerization protein (DP) family, which includes DP 1 and
DP2 (Krek et al. 1993;Wu et al. 1995). These heterodimers associate with the pocket
proteins and recruit further regulatory proteins to form complexes in order to regulate
the transcriptional machinery. Members of the E2F family can be segregated on the
basis of their binding affinities for the various pocket proteins and their predominant
effect on transcription into either activators or repressors of transcription (reviewed
(Trimarchi et al. 2002). Initially there was little evidence to suggest that individual
E2Fs showed specificity for particular E2F responsive promoters (Flemington et al.
1993;Takahashi et al. 2000;Wells et al. 2000). However, there is now increasing
evidence pointing to some degree of specificity, and this might explain the different
effect of loss of individual E2F members in specific E2F knockouts (Attwooll et al.
2004).
Most ofwhat is known of the function of the E2F family is confined to the first 5
E2F members to be identified (E2F1 E2F2, E2F3a, E2F4 and E2F5).
E2F1,2,3a: Activators of Transcription
E2F1, E2F2 and E2F3a are the predominant transcriptional activators of the E2F
family. Each can form a heterodimer with either DPI or DP2 to give functional
transcriptional activity, and these complexes preferentially bind Rb rather than pi07
or pl30.These three E2F proteins show high levels of homology in their structure,
DNA binding and transactivation properties. Over-expression of activator E2Fs
drives quiescent cells into S phase (Johnson et al. 1993;Vigo et al. 1999), can
override inhibitory growth arrest signals, including TGFB and CKI activity,
(DeGregori et al. 1995b;Mann et al. 1996), and can lead to the transformation of
primary cells (Johnson et al. 1994;Xu et al. 1995). Alternatively, antibody mediated
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inhibition ofE2F3 causes cell cycle arrest (Leone et al. 1998a), and E2F3 deficient
MEFs have reduced rates of proliferation (Humbert et al. 2000). Inhibition of all
three E2Fs can completely block cell proliferation (Wu et al. 2001). Levels of
activator E2F appear to vary temporally, being highest early in S phase, and
generally absent, or expressed at low levels, during quiescence (Aguilar et al.
1994;Dyson 1998).
The transcriptional activity of the activator E2Fs is tightly regulated through
association with the pocket proteins, particularly pRb. Phosphorylation of the pocket
protein region of pRb abolishes this association and results in increased E2F activity.
Functional inactivation of pRb causes deregulated E2F activity and unscheduled
proliferation (Sage et al. 2003). Loss of either E2F1 or E2F3 is sufficient to reduce
not only the abnormal proliferative phenotype resulting from Rb inactivation, but
also suppress the p53-dependent and p53 independent apoptosis that is characteristic
of deregulated E2F activity (Sage et al. 2000;Tsai et al. 1998). Furthermore, loss of
E2F-1 reduces tumour development in mice heterozygous for Rb and increases the
life span of such animals (Yamasaki et al. 1996a).
E2F4.5: Repressors of Transcription
E2F4 and E2F5 are the predominant repressors of transcription and differ
significantly in their structure from E2Fl-3b. Importantly, members of this E2F
repressor group contain a nuclear export signal (NES) (Boveri T 1914;Lindeman et
al. 1997). (Figure 3, page 26). This export signal is absent in the activator group,
which has instead a nuclear localisation signal (Muller et al. 1997b). In addition, the
repressor E2F members show different pocket protein binding affinities compared to
the activator E2F group; E2F4 can interact with all three pocket proteins (pRb, pi07
and pi30) at different points through the cell cycle, E2F5 binds only to pi30.
Although high levels of expression of E2F4 and E2F5 can bring about slight
increases in cell cycle gene expression, they are poor transcriptional activators
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(DeGregori et al. 1997). E2F4 and 5 appear to repress transcription by blocking
interaction of the E2F activators with their target genes through formation of
repressor complexes with pi07 and pi30. Consistent with their role as transcriptional
repressors, E2F 4 and 5 appear to be required for exit from the cell cycle and
terminal differentiation insomuch as cells lacking repressor E2Fs fail to respond to
cell cycle arrest signals (Gaubatz et al. 2000;Mann et al. 1996). Mutation of E2F
binding sites within E2F responsive gene promoters produces insensitivity to growth
arrest signals and results in increased transcription. This demonstrates the importance
of these repressor complexes in the negative regulation of the cell cycle (Li et al.
1997). Importantly, chromosome immunoprecipitation (ChIP) studies have
demonstrated the association of such repressor complexes with many E2F responsive
promoters during quiescence. In these studies, repressor E2Fs are replaced by the
activator E2Fs as cells progress from G0/G1 toward S phase; a change that correlates
with the induction of E2F dependent gene expression (Takahashi et al. 2000).
The division ofE2F1-5 on the basis of their activity into activators and repressors is
dependent on their preferential association with different pocket proteins, and also on
their sub cellular localisation. When the pocket proteins are phosphorylated by rising
cdk activity, the free E2Fs are directed in different directions. The activators are
localized to the nucleus where they can effect transcription by virtue of their nuclear
localisation signal, whereas the repressors are directed towards the cytoplasm
(Mulleretal. 1997a;Verona et al. 1997).
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Figure 3 All of the E2F members have specific domains for DNA binding and
dimerization with the DP proteins. The Activator E2Fs have a Nuclear Localization
Signal, the Repressor E2Fs 4 and 5 have a Nuclear Export Signal. All E2Fs have a
transactivation domain with the exception of E2F6 which shares little homology with
the rest of the group and has a unique region for the binding of the Polycomb
Complex. (Trimarchi and Lees 2002)
Latest members of the E2F family; E2F3b, E2F6 and E2F7.
The newest members of the E2F family to be identified include E2F3b, E2F6 and
E2F7. E2F3b is transcribed from a distinct locus of the E2F3 gene, and in complex
with pRb acts predominantly as a repressor of transcription during quiescence (Leone
et al. 2000). E2F6 and E2F7 do not bind to the pocket regions of the pocket proteins,
nor do they possess transactivation domains, yet nonetheless they do repress
transcription (Gaubatz et al. 1998;Leone et al. 2000). E2F6 mediates this repression
through association with the Polycomb proteins (PcG), a group of proteins which
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repress transcription through modification of chromatin structure (Trimarchi et al.
2001). How E2F7 mediates transcriptional repression is not clear.
Mechanisms of Transcriptional regulation by Rb/E2F
The complex of Rb and E2Fs mediate transcriptional regulation through a number of
different mechanisms.
Firstly, the pocket proteins bind to and physically block the transactivation domain of
the E2F transcription factors (Flemington et al. 1993;Helin et al. 1993), inhibiting the
ability of the E2F members to induce the transcriptional machinery.
Secondly, the pocket protein/E2F complex recruits chromatin remodelling enzymes
to form "repressor complexes". A large body of work has demonstrated E2F
mediated transcription is coincident with significant chromatin structural changes
that are known to influence the transcriptional machinery (reviewed (Frolov et al.
2004;Harbour et al. 2000;Zhang et al. 2001). Rb, pl07 and pl30 all possess
additional binding sites, distinct from their E2F binding sites, which can associate
with chromatin remodelling enzymes. When bound to E2F, these chromatin
remodelling complexes are recruited to the E2F responsive promoters. The
modification of histones, which constitute a structural element of chromatin, is
known to regulate transcription via conformational change of the DNA. Potential
histone modifications include the addition or removal of acetyl groups,
phosphorylation and methylation. The pocket proteins can associate with histone
deacetylase (HDAC) enzymes, which can remove acetyl groups from histones
resulting in the condensation of nucleosomes into chromatin. This inhibits
transcription by hindering the access of transcription factors to the promoters.
Conversely, hyperacetylation by histone acetyltransferases (HAT) is thought to cause
conformational changes to the chromatin which might stimulate transcription. In mid
to late G1 the replacement of the repressor complex pl07/E2F4 by pRb/E2F
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activator complexes is associated with the appearance ofHAT and concomitant
histone hyperacetylation (Rayman et al. 2002). Whether these modifications are
simply coincident with the switch of repressor and activator binding, or an important
mechanism of pocket protein mediated transcriptional repression is still unclear.
Rb/E2F and Regulation of apoptosis
In addition to ectopic cell cycling, increased E2F activity resulting from either over-
expression of E2F or loss of Rb, results in increased apoptosis in a number of
different experimental systems (Almasan et al. 1995;DeGregori et al. 1997;Pan et al.
1998;Shan et al. 1994;Symonds et al. 1994;Tsai et al. 1998). Initially, the ability to
induce apoptosis was believed to be a unique property of E2F1 (Kowalik et al. 1998),
but pro-apoptotic properties have since been demonstrated for both E2F2 and E2F3
(Leone et al. 1998b). Loss of E2F suppresses both unscheduled proliferation and
apoptosis in Rb null mice (Takahashi et al. 2000;Tsai et al. 1998). In the central
nervous system (CNS) of developing Rb null mice, loss of both E2F1 and E2F3, but
not E2F2, inhibits apoptosis (Saavedra et al. 2002).
E2F can mediate apoptosis through a number ofdifferent pathways, both p53-
dependent and p53-independent, which appear to vary according to cellular context
(reviewed (Bell et al. 2004;Ginsberg 2002;Trimarchi et al. 2002). One of the earliest
suggested pathways of p53 stabilisation by E2F was through the transcriptional
activation ofpl4ARF, which is an acknowledged transcriptional target of E2F1
(Bates et al. 1998;DeGregori et al. 1997). pl4ARF sequesters the protein HDM2
(MDM2 in the mouse) which normally binds to, and targets, p53 for ubiquitination
and degradation. Thus, increased pl4ARF levels result in increased levels of active
p53. It has also been demonstrated that p53-dependent E2F mediated apoptosis can
occur in the absence of pl4ARF (Tolbert et al. 2002;Tsai et al. 2002). Alternative,
less well characterised pathways of pl4ARF-independent E2F mediated stabilisation
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of p53 might include a direct pathway whereby the Cyclin A binding domain of
E2F1 binds directly to, and stabilises, p53 following DNA damage (Hsieh et al.
2002). A second important alternative pathway is that of increased activity of the
DNA damage inducible kinases, such as the ataxia telangiectasia-mutated protein
(ATM) (Powers et al. 2004).
Potential p53-independent pathways ofE2F mediated apoptosis include activation of
the p53 homolog, p73 (Irwin et al. 2000). E2F1 increases transcription of p73 which
directly links to the apoptotic machinery, ultimately leading to apoptosis. E2F1 also
directly increases the expression of apoptosis protease activating factor 1 (Apafl),
which can lead to activation of caspases that are the ultimate downstream effectors of
apoptosis (Furukawa et al. 2002;Nahle et al. 2002).
E2F1 may also induce apoptosis through inhibition of anti-apoptotic signalling
pathways, such as disruption of the tumour necrosis factor (TNF) survival pathway
(Phillips et al. 1999).
The characteristic apoptosis seen in Rb deleted systems suggests an active role for
Rb in the suppression of apoptosis. The significance of these findings remains
unclear. Apoptosis is not a natural consequence of the de-activation of pRb and
consequent increase in E2F activity which occurs during the normal cell cycle. This
has lead to the suggestion that apoptosis seen in experimental systems functions as an
escape pathway for de-regulated cell cycle activity. Loss of this escape mechanism
through, for example, loss of p53, increases tumorigenicity in Rb chimaeras (Harvey
et al. 1995;Williams et al. 1994b). However, apoptosis is not an obligatory feature of
Rb knockout systems and does not, for example, occur following conditional Rb
deletion in the CNS (MacPherson et al. 2003). The occurrence of both unscheduled
proliferation and increased apoptosis in these experimental systems suggests E2F
could function as both a tumour suppressor and an oncogene. Fitting with its role as
an oncogene, over-expression of E2F promotes cell cycle entry in quiescent cells
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(Attwooll et al. 2004), and loss ofE2F delays the development of pituitary tumours
in Rb chimaeras (Yamasaki et al. 1998). Conversely, E2F null mice develop tumours
(Yamasaki et al. 1996b), and loss of E2F suppresses the apoptosis seen in mice
heterozygous for Rb (Field et al. 1996). These observations suggest a role for E2F as
a tumour suppressor. Different models have been proposed in an effort to explain this
apparent paradox. In the "conflict model", apoptosis may result from the conflict
between the differentiation and unscheduled proliferation that occurs in Rb null
embryos, with apoptosis as the default escape pathway (Chau et al. 2003). A
modification of this model suggests a "threshold" of proliferation above which
unscheduled proliferation triggers apoptosis (Trimarchi et al. 2002). Therefore,
during the normal cell cycle Rb inactivation and E2F activity do not trigger apoptosis
because this level of proliferation is below the required "threshold". A further,
alternative explanation is that the inhibition of apoptosis is one of the prime functions
of pRb, and that the apoptosis seen in Rb deleted systems is not primarily a response
to unscheduled proliferation, but rather a reflection of the loss of the anti-apoptotic
activity of pRb. Expansion of this idea has lead to the suggestion that pRb may
function as a predominant regulator of both apoptosis and proliferation via
differential activities at E2F-responsive apoptotic and proliferative genes. However,
such a dual role for pRb has yet to be determined conclusively.
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Section B
Liver Regeneration
The liver possesses a unique ability to regulate its size in order to meet the
physiological requirements of the body. Although hepatocytes appear to be
terminally differentiated, highly specialised cells with an extremely slow rate of cell
turnover, these cells can, when required, proliferate rapidly to balance metabolic
demand against liver function. This is demonstrated most dramatically in the rapid
regenerative response that occurs following acute hepatic insufficiency, exemplified
in the surgical model of partial hepatectomy.
Models of regeneration.
1.Hepatectomy
The experimental model of partial hepatectomy (PH) was first described in the
1930's by Higgins and Anderson when they demonstrated that following removal of
70% of the rat liver, restoration of liver tissue mass occurred within 14 days (Higgins
et al. 1931b). Consequently, investigators demonstrated the rapidity with which
apparently quiescent hepatocytes divide following PH, and showed that the number
of dividing cells was proportional to the amount of liver resected (BUCHER et al.
1964).
Hepatectomy produces a compensatory hyperplasia, with hepatocytes in the
remaining liver dividing to produce an anatomically different organ. This contrasts
with the regeneration seen in cytotoxic liver damage, where repair brings about
restoration of the original liver anatomy. Post hepatectomy, replication begins in the
hepatocytes surrounding the portal triad, with waves of replication sweeping
outwards towards the pericentral regions (Michalopoulos et al. 1997). Hepatocyte
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replicative activity, as estimated by DNA synthesis, reaches its peak in the rat at 24
hours post surgery, and in the mouse at 36 hours. In larger animals the maximal rate
of proliferation occurs later; 72-96 hours in canines and 7-10 days in primates
(Koniaris et al. 2003a). It is estimated the majority of hepatocytes divide one to two
times. The replication of hepatocytes is followed sequentially by that of biliary duct
cells, Kupfer cells, Stellate cells, and finally, endothelial cells.
Although each hepatocyte replicates only once or twice, this belies the true
replicative potential of the mature hepatocyte. This potential has been neatly
demonstrated by a series of rescue transplantations of labelled normal hepatocytes
into mice with engineered liver failure. The transplanted hepatocytes repopulate over
90% of the diseased recipient liver. The donor hepatocytes can be identified and
on
serially transplanted more than 8 times; equivalent to a 7.3 x 10 clonal expansion of
the original population. (Overturf et al. 1997)
Such replicative potential raised doubts as to whether a mature differentiated cell
could behave in such a way, and it was proposed there must be, within this
population of replicating cells, actual stem cell progenitors responsible for such
expansion (Sell 1990b). Such cells have certainly been identified and termed "oval
cells", according to their morphology. Where controversy has reigned is the different
roles these cells have been ascribed by various investigators in terms of their
contribution to both replication in the short term, and hepatocarcinogenesis in the
longer term (Fausto et al. 2003;Fausto 2004b;Sell 2001). There is little doubt that in
particular experimental models, such as following the administration of retrosine,
inhibition ofmature hepatocyte proliferation occurs, emphasising the role of a
progenitor population (Thorgeirsson et al. 2003), but the importance of such a cell
subpopulation in liver disease remains controversial.
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2. Liver repair following acute injury
Where the model of hepatectomy potentially provides a "clean" method for
unravelling the intricacies of regeneration, many other toxin-induced methods of
inducing regeneration exist (Koniaris et al. 2003a). One of the most established is the
administration of carbon tetrachloride (CCL4). CCL4 is a hepatotoxin which, when
injected into the peritoneal cavity, causes maximal necrosis in the central regions of
liver lobules (zone 3) at around 24 hours post treatment. In this case, the proliferative
response is more correctly termed regeneration because the repair response results in
restoration of the previous anatomical structure. This involves an orchestrated
inflammatory response, with removal of necrotic tissue and replication of
neighbouring hepatocytes. The regenerative response following CCL4 treatment is
similar to that following PH, although the cell cycle entry of hepatocytes is not as
synchronous, and the peak ofDNA synthesis occurs a little later.
Chronic liver injury has been modelled using either chronic toxin administration
(Constandinou et al. 2005), or by the generation of transgenic mouse models (Sell
2003b).
Phases of regeneration
The regenerative events which follow hepatic resection or acute hepatic necrosis
have been divided into different phases, allowing sequential consideration of those
factors which are important in the restoration of functional liver mass. A number of
key factors orchestrate the regenerative response including cytokines, growth factors
and enzymes which modify the extracellular matrix. The interplay of such factors
brings about a cascade of transcriptional activity with different banks of genes
transcribed at different points following hepatectomy. (Fausto 2000a;Koniaris et al.
2003b;Taub 2003;Taub 2004).
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The elusive start signal for liver regeneration
In the adult liver, hepatocytes are quiescent and the rate of hepatocyte replication is
extremely low, with only 1 in 20,000 hepatocytes undergoing mitosis at any given
time (Fausto et al. 1994). Neither the factors which keep hepatocytes in quiescence,
nor those which initiate replication have been determined. It may be that the start
signal for regeneration is insufficiency of liver function which occurs following loss
of functional liver mass. How such physiological insufficiency initiates liver
regeneration is not yet established.
Priming.
Priming is a reversible and non-committal period immediately following
hepatectomy during which hepatocytes move from GO to Gl. During priming, a
change in the sensitivity of hepatocytes to growth factor stimulation occurs. Priming
can be induced experimentally through non-specific exogenous stimuli including
sham surgery, dietary protein deprivation, or collagenase perfusion (Liu et al.
1994).The key events occuring in this period include remodelling of the extracelular
matrix (ECM), which may be important in the early release of hepatocyte growth
factors (reviewed (Mangnall et al. 2003), and the transcription of a bank of so called
"immediate early genes". Factors which are thought to be important during the
priming phase of liver regeneration are shown in Figure 4, on page 38.
Immediately following hepatectomy there is an increase in gut-derived factors, such
as lipopolysaccharide (LPS), which reach the liver via the portal blood supply. LPS
activates various cell types in the liver including endothelial cells, Kupfer cells and
Stellate cells, which in turn produce a number of soluble mediators that render
hepatocytes responsive to subsequent growth factor stimulation. Such factors include
the cytokines tumour necrosis factor a (TNFa ) (Yamada et al. l997;Yamada et al.
1998) and interleukin 6 (IL-6) (Li et al. 2001). The increase in levels ofTNFa and
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IL-6 results in activation of pre-existing transcription factors including nuclear
transcription factor kB (NF-kB) (FitzGerald et al. 1995), and STAT 3 (Cressman et
al. 1994). Along with the immediate targets ofNF-kB and signal transducer and
activator of transcription 3 (STAT 3), there is a bank of immediate early genes which
are transcribed in the first hour following hepatectomy. More than one hundred such
immediate early genes have been identified by gene array experiments (Arai et al.
2003;Su et al. 2002).
The immediate early genes contain many transcription factors, including families of
proto oncogenic transcription factors such as c-fos, c-myc and c-jun. These
transcription factors then induce the expression of the delayed early genes and
consequently amplify a cascade of transcription to bring about progression from G1
to S phase.
Progression Phase and Growth Factor Stimulation
Following priming, hepatocytes are responsive to, and indeed reliant upon, mitogenic
stimulation to progress into S phase. Such cytokines including hepatocyte growth
factor (HGF), epidermal growth factor (EGF), and transforming growth factor alpha
(TGFa), are termed complete mitogens because they bring about DNA synthesis in
cells in vitro. Of these, HGF is arguably the most potent. HGF levels increase rapidly
and remain elevated for 3 days following hepatectomy (Lindroos et al.
1991;Zarnegar et al. 1995). There are a number of potential sources ofHGF
including liver Stellate cells (Schirmacher et al. 1992), the ECM of the liver (Kim et
al. 1997;Masumoto et al. 1993), and non-hepatic sources including the
lung.(Yanagita et al. 1992) HGF stimulates hepatocyte proliferation and has
pleiotropic effects on a number of mitogenic signalling pathways. The regenerative
response to CCL4-induced liver injury can be blocked using antibodies against
HGF(Burr et al. 1998). Constitutive over-expression ofHGF in mice leads to
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increased basal rates of hepatocyte proliferation and a two fold increase in the
proliferative rate in response to hepatectomy (Shiota et al. 1998). Although it should
be noted that these mice do not develop liver tumours, over-expression of TGFa
produces mice with enlarged livers that demonstrate increased rates of hepatocyte
proliferation and, as a consequence, develop liver tumours (Webber et al. 1994).
Antibodies against TGFa reduce DNA synthesis following hepatectomy (Tomiya et
al. 2000). TGF null mice develop normally (Mann et al. 1993), presumably because
of a functional overlap with EGF. In the absence of a priming stimulus, these
mitogens do not induce any real increase in hepatocyte proliferation when
administered in vivo (Roos et al. 1995).
Those genes up-regulated during the progression phase, the so called "delayed early
genes", include anti-apoptotic genes such as bcl-2 and many of the cell cycle genes
including Cyclin Dl, p53, p21 and pl9 (Fausto 2000b). These proteins of the cell
cycle orchestrate the now committed path from the restriction point to DNA
synthesis and mitosis
Termination of Liver Regeneration
Hepatocytes move rapidly from quiescence to active replication and, upon restoration
of functional liver mass, cell division ceases almost as quickly. The signals which
terminate cell replication are not yet well understood. It may be that cessation of
replication does not require a "stop" signal as such, but simply represents a return to
a stable state (Bellamy 1997).There are situations, however, when an involution of
the liver occurs. This is seen when over-sized orthotopic liver transplants undergo
apoptosis in order to meet the physiological demands of the host (Francavilla et al.
1988) and suggests an active, rather than passive, method of halting hepatocyte
replication.
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The prime candidate for the cessation of hepatocyte division following hepatectomy
is TGFB and related family members, including activin. TGFB is produced mainly by
Stellate cells. Though the role of TGFB is complex, there is little doubt it has potent
growth inhibitory effects on hepatocytes in vitro and in vivo. TGFB levels are
normally very low in quiescent liver, increase steadily following hepatectomy, and
peak 2-3 days post surgery (Bissell et al. 1995). Exogenous TGFB reduces rates of
DNA synthesis following hepatectomy (Russell et al. 1988). But this occurs only
when administered during late G1 and the effect is short lived. In this context, TGFB
probably acts through p21 and p27 to inhibit G1 Cyclin/cdk activity and prevents cell
cycle progression by blocking the phosphorylation of pRb. The over-expression of
TGFB in transgenic mice leads to increased apoptosis, liver cirrhosis and, as a result,
hepatocyte replication (Sanderson et al. 1995). Following hepatectomy, mice with
conditional liver-specific deletion ofTGFB receptor 2 demonstrate increased levels
of proliferation and increased liver mass:body weight ratio compared to control
animals (Romero-Gallo et al. 2005). However, an intact TGFB signalling pathway is
not required for termination of regeneration (Oe et al. 2004). Therefore, although
there is evidence to demonstrate TGFB has an inhibitory role to play in the regulation
of regeneration, its role in the return to quiescence following regeneration remains
unclear.
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Partial Hepatectomy
Thyroid Pancreas Adrenal Duodenum
Figure 4. Schematic representation of those factors important in triggering hepatocyte replication following partial hepatectomy.(Taub 2004)
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Apoptosis in Liver Regeneration
Apoptosis allows the elimination of defective hepatocytes which are either unable to
go through replication, or whose replication has gone awry during regeneration.
Apoptosis can be effected by ligation of cell-surface death receptors or be initiated
by mitochondria degradation. The Bcl-2 family of proteins is amongst the most
important of the upstream regulators of mitochondrial-induced apoptosis. The family,
which contains both pro- and anti-apoptotic genes, controls the down stream
effectors of apoptosis, leading ultimately to digestion of the nucleus and destruction
of the cellular DNA. The prevalence of apoptosis is normally reduced following PH
(Helvering et al. 1993) due to an upregulation of a number of anti-apoptotic members
of the Bcl-2 family, most notably Bcl-2 and Bcl-XL (Bergelson et al. 1997). This up¬
regulation of anti-apoptotic Bcl-2 members may be mediated by pro-proliferative
factors, such as IL-6. IL-6 null mice exhibit elevated expression of pro-apoptotic
signals resulting in hepatocyte death and increased mortality (Kovalovich et al.
2001). p53 is normally expressed at very low levels in quiescent hepatocytes. p53
mRNA and protein levels increase at around 16 hours following hepatectomy, and
decrease to basal levels by 18-24 hours (Thompson et al. 1986). p53 null mice show
faster rates of proliferation following hepatectomy compared to wild type controls
(Sell 2003a). Higher rates of proliferation in the absence of elevated levels of
apoptosis result in an increase in both the number and density of cells in the
regenerated liver compared to controls. This seems to imply a role for p53 as a
negative regulator of regeneration (Yin et al. 1998). Levels ofD cyclins and cdks 2
and 4 are also increased in p53 null mice (Yin et al. 1998).
Abnormal apoptotic activity is believed to be an important mediator of cell loss in a
variety of liver disease states, including steatosis and cirrhosis, and to be a mediator
of liver damage following transplantation (Guicciardi et al. 2005).
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Maintenance of liver function during liver regeneration
Liver function is essential for life, and how the liver maintains homeostasis whilst
hepatocytes are dividing is an important unanswered question. Among the bank of
immediate early genes that are upregulated following hepatectomy are those which
regulate gluconeogenesis. The remaining liver remnant increases its gluconeogenic
activity to compensate for loss of liver mass, thus maintaining glucose homeostasis
(Haber et al. 1995). The ability of the liver to maintain such function relies on an
interplay between those genes which are normally expressed during quiescence, and
those which are upregulated during regeneration (Leu et al. 2001).
Rb pathway in liver regeneration
A number of components of the Rb pathway have been studied in liver regeneration,
during which levels of cell cycle mediators change rapidly. What remains unclear is
how each of these components controls regeneration, and to what extent they
contribute to the maintenance of quiescence.
Levels ofCyclin D and Cyclin D/cdk 4 activity rise rapidly following hepatectomy.
In mice, the level ofCyclin D1 mRNA (the predominant murine form) increases
significantly 12 hours following hepatectomy, with maximum levels occurring at 48-
72 hours. This is followed by rapid increases in Cyclin Dl/cdk4 complex formation
and kinase activity. (Albrecht et al. 1998a). Transient over-expression of Cyclin D1
using an adenoviral delivery system is sufficient to produce DNA synthesis, mitosis
and liver enlargement in mice.(Nelsen et al. 2001c).
Levels of both p21 and p27 are low in the quiescent liver and are upregulated by post
transcriptional mechanisms following hepatectomy (Albrecht et al. 1997;Albrecht et
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al. 1998b). Increased levels of p21 are also found in human liver disease, where they
correlate with markers ofproliferation (Crary et al. 1998). Over-expression of p21 in
transgenic mice leads to inhibition of postnatal hepatocyte proliferation with
abnormal liver development and a blunted regenerative response to hepatectomy
(Wu et al. 1996). Although homozygous p21 null mice show normal liver
development, they exhibit an increased rate ofmitosis during the proliferative
response to hepatectomy (Albrecht et al. 1998b;Dyson et al. 1989;Hu et al. 1990).
However, this is not accompanied by increased tumorigenesis. A potential role for
p21 in the maintenance of quiescence has not yet been proven.
During quiescence hypophosphorylated pi07 and pRb are expressed at low levels,
whilst pi30, which is found in both hypophosphorylated and phosphorylated forms,
is expressed at higher levels (Garriga et al. 1998). During liver regeneration, levels of
hyperphosphorylated pi 07 and pi 30 increase with concomitant dissociation of the
E2F/pl30 complex. Levels of hyper-phosphorylated Rb increase following
hepatectomy, and are at their greatest levels during S phase. (Fan et al. 1995). Over-
expression of E2F-1 results in higher basal rates of hepatocyte proliferation and sees
the early development of preneoplastic lesions in mice. However, increased E2F-1
expression has no effect on rates of proliferation following hepatectomy (Conner et
al. 2000). Homozygous E2F-1 null mice exhibit normal proliferation following
hepatectomy (Lukas et al. 1999).
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Section C.
Polyploidy in the Liver
Polyploidy is a feature of all mammalian tissues, but along with binuclearity, is a
particularly common feature of the adult liver. The proportion of polyploidy cells in
rodents increases from birth. In the neonatal rat hepatocytes are exclusively diploid
(2n) (Ravid et al. 2002b), with polyploidisation beginning after weaning (Sigal et al.
1999), and continuing throughout life as a physiological feature of ageing. In rats the
proportion of tetraploid cells may be as many as 70% and tends to be lower than in
humans (Seglen 1997). Levels ofpolyploidisation in the mouse tend to be higher in
males than in females. (Lu et al. 1993)
The normal physiological process by which polyploidisation occurs in hepatocytes
was determined by Guidotti et al using time lapse video microscopy (Guidotti et al.
2003). The process involves first the generation of the binuclear cell, which occurs
through mitosis without cell division (acytokinesis). Subsequent mitosis of the
binuclear cell then leads to two 4n daughter cells. (Figure 5, page 45)
During liver regeneration following PH there is an increase in hepatocyte ploidy,
with an increase in the number of octaploid cells and a fall in the percentage of
diploid cells (Gandillet et al. 2003). There is also a concomitant fall in the percentage
of binuclear cells, which presumably undergo acytokinesis to form cells of higher
ploidy (Brodsky et al. 1977). Thus, following PH there is a shift in the nuclear
content to that of a higher ploidy. This shift persists for months following surgery.
An interesting characteristic of those hepatocytes of higher ploidy found following
PH, is that they appear to exhibit markers of cellular senescence, including 13-
galactosidase expression, and show attenuated proliferative capacity in vitro (Sigal et
al. 1999). In vitro, hepatocytes of higher ploidy also show lower rates of proliferation
in response to mitogens, such as insulin and EGF, compared to diploid cells (Mossin
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et al. 1994). In murine transgenics which express mitogens such as TGFa (Webber et
al. 1994) or HGF (Shiota et al. 1994), the proportion of diploid cells is increased.
This fits with the observation that diploid cells are more sensitive to proliferative
signals than cells in the same liver of higher ploidy.
The cellular mechanisms which determine ploidy have yet to be determined.
Acytokinesis is dependent on the uncoupling of S phase from mitosis. This has
focussed the dissection of the potential polyploidisation pathway on proteins which
regulate the cell cycle. p21, initially identified as a senescence factor can induce cell
cycle arrest at the G2/M check point, so preventing mitosis (Wu et al. 1996). Over-
expression of p21 increases levels of polyploidy following hepatectomy (Wu et al.
1996), and conversely, levels of ploidy are reduced following PH in p21 null mice.
p21 is a downstream effector of stabilised p53, and mice homozygous for p53
deletion show decreased levels of polyploidy (Bellamy et al. 1997).
Levels ofploidy in the liver appear to be altered in disease states. In animal models
of carcinogenesis, diethylnitrosamine (DEN) treatment leads to an expansion of the
diploid cell population (Schwarze et al. 1984b). In humans there is a similar shift,
with higher proportions ofdiploid cells found in preneoplastic nodules (Hoso et al.
1991) and in hepatocellular carcinomas (Saeter et al. 1988c) than in surrounding
tissue. There is a similar shift following chronic hepatitis infection (Anti et al. 1994),
although more recent studies have used different methods to demonstrate increased
levels of ploidy in viral hepatitis (Toyoda et al. 2005).
The biological function of polyploidisation is not clear. It has been suggested that
acytokinesis allows a cell to increase its size, mass and metabolic output, without
expending the energy required for cell division (Ravid et al. 2002a). This may be of
benefit to the rapidly dividing hepatocyte following hepatectomy. In addition,
multiple gene copies may allow the polyploidy cell to resist the mutational effects of
oxidative damage, to which the liver is particularly exposed.
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An attractive theory is that polyploidisation is a biological defence mechanism.
Although they remain metabolically active, high ploidy hepatocytes demonstrate a
decreased ability to respond to mitogenic signals (Seglen 1997), an increased
susceptibility to apoptosis (Oren et al. 1999), and a resistance to genetic mutation due
to multiple gene copies (Schwarze et al. 1984c). Those hepatocytes of high ploidy,
whose fraction greatly increases following hepatectomy, exhibit markers of oxidative
DNA damage (Gorla et al. 2001b). In a mutant model ofWilson's disease, the LEC
rat, (Long-Evans rat with a cinnamon-like color), there is extensive oxidative liver
injury accompanied by lipid peroxidation, which presumably occurs due to
accumulation of copper. In LEC rats high levels of polyploidy preceed the
development of cirrhosis and HCC (Terada et al. 1999). Transgenic mice deficient in
pathways ofDNA repair enzymes accumulate markers ofDNA damage and show
high levels of ploidy (Chipchase et al. 2003). Is polyploidisation a safety net for the
aging, or damaged, hepatocyte? Is it a perturbation of the polyploidisation process,
even an exhaustion of this process, which brings about, in the recurrently damaged
and regenerating liver, the expansion of a diploid population from which potentially
malignant clones may arise in an environment of chronic inflammation? The
biological relevance ofpolyploidy in the liver remains to be determined.
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Figure 5. Schematic representation of polyploidisation during hepatocyte division. Rounds of acytokinetic mitoses increase ploidy followed





Hepatocellular carcinoma (HCC) is one of the most common forms of gastro
intestinal malignancy worldwide. In 1990 there were approximately 437,000 new
cases worldwide, rising to 564,000 new cases in 2000 (Parkin et al. 2001) with
almost as many deaths. There is a significant geographic variation (Bosch et al.
1999b), with the incidence of hepatocellular carcinoma higher in developing,
compared to developed, countries with the highest incidences found in Eastern Asia,
middle Africa and West Africa. Annual age adjusted incidence rates may be as high
as 48 per 100,000 in men in Western Africa. In the UK, the male age corrected
incidence is currently between 4.5-5.4 cases per 100,000 and increasing (Office for
National Statistics 2004). The stark differences in geographical incidence which
occur not just between countries, but also within countries, reflect differences in
exposure to known risk factors. Dominant among aetiological factors is chronic
infection with viral Hepatitis B (HBV) or Hepatitis C (HCV). The combined effect of
persistent HBV or HCV infection accounts for over 80% ofHCC cases worldwide
(Bosch et al. 1999b). HBV infection accounts for the majority of cases of HCC in
Asia and Africa. In the West and Japan HCV infection is the main risk factor, in
addition to other causes of cirrhosis including alcohol and haemachromatosis (Llovet
et al. 2003). There is thought to exist a synergism between aetiological factors
(Hassan et al. 2002). The disease is more common in men than in women, with a sex
ratio varying between 1.5 and 3.0 (Llovet et al. 2003)
The incidence of HCC has been increasing slowly and there is an anticipated increase
in the USA related to the current prevalence ofHCV that is expected to last for the
next two decades (El Serag et al. 1999;E1 Serag et al. 2003;Mizokami et al.
46
2004;Tanaka et al. 2002). HCC is now the leading cause of death in Europe amongst
those with cirrhosis (Fattovich et al. 2004). This rising incidence has increased
concern and interest in possible diagnostic, treatment, and prevention strategies for
HCC (Hoofnagle 2004).
Treatment
The once dismal prognosis ofHCC seems to be improving, certainly in developed
countries where earlier diagnosis allows consideration of potentially curative
treatments. Such treatments for "early" HCC include surgical resection (Inoue et al.
2004), liver transplantation (Llovet et al. 2000a;Suarez et al. 2000), and percutaneous
treatments. This last group includes hepatic artery chemoembolisation (Llovet et al.
2000b) and ablative therapies such as alcohol injection and radiofrequency (Allgaier
et al. 1999), which have been proven to be effective in certain patient groups.
Outcome is determined by various factors including the severity of background liver
disease, the treatment modality and the size, number, and behaviour of the tumour(s).
Although the survival for this group of patients who are amenable to radical
treatment is improving (Arii et al. 2000;Llovet et al. 1999;Mazzaferro et al. 1996),
there is considerable variation in treatment outcomes and survival between different
treatment groups, and this may be a reflection of the biological heterogeneity of these
tumours. In the UK and USA survival rates following diagnosis ofHCC are
approximately 5-8%, 5 years following diagnosis of the disease (Ryder 2005)
Morphological changes in the development of HCC
There are common morphological characteristics seen during the development of
HCC which include:
• Chronic liver injury with inflammation





A simplified representation ofwhen these observed morphological changes may be
seen in the development of the disease is shown below (Figure 6Error! Reference
source not found..)
\ A 4/ phenotypicallyaltered foci dysplastichepatocytes hepatocellularcarcinoma
preneoplasia
(10 to 30 years)
dysplasia _
(2 to 5 years)
Figure 6 Schematic representation of the suggested chronological sequence of events
in the development of HCC.
Chronic hepatitis is characterised by prolonged inflammation of the liver with
inflammatory cell infiltrate, hepatocyte death and constant hepatocyte proliferation to
replace dead hepatocytes. An inflammatory infiltrate of lymphocytes, plasma cells
and macrophages permeate the liver parenchyma and bring about killing of damaged
hepatocytes, predominantly through activation of death signalling pathways (Kagi et
al. 1996;Yoong et al. 1998). Recruitment of these inflammatory cells is driven
through increased expression of chemotactic cytokines and upregulation of
appropriate cell adhesion molecules by the endothelial cells of the portal tracts
(Yoong et al. 1998). These inflammatory cells in turn express multiple cytokines,
including interferons and chemotactic cytokines, which recruit further populations of
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inflammatory cells and increase endothelial cell expression of adhesion molecules
and receptors for inflammatory cell ligands. The resulting balance of cytokines
induces hepatocyte death via cytotoxic T cell-mediated killing and pro-inflammatory
cytokines such as TNFa, which induce apoptosis. Hepatocytes divide and regenerate
in response to growth factors in the inflammatory infiltrate and to replace dead
hepatocytes in order to maintain liver function.
As a consequence of chronic inflammation the architecture of the liver is grossly
altered. Inflammation and necrosis induce cirrhosis, which is a diffuse hepatic
fibrosis characterised by deposition of a collagenous matrix whose septa segregate
the normal liver parenchyma into liver nodules.(Anthony et al. 1978;Yoong et al.
1998). The development of cirrhosis is the greatest risk factor for the development of
HCC in humans, although HCC can develop in non-cirrhotic livers (La Vecchia et al.
1998).
Regeneration in the context of chronic inflammation induces nodular aggregates of
rapidly proliferating, often monoclonal, populations of hepatocytes. Such groups of
hyperplastic hepatocytes often display abnormal phenotypic changes which are
among the earliest morphological changes associated the development ofHCC.
These foci of altered hepatocytes (FAH) show metabolic abnormalities, such as
increased production and storage of glycogen, producing characteristic clear cell
FAH, or increased expression ofRNA, which produces characteristic basophilic
staining FAH. Such foci were first described in the liver adjacent to HCC (Schulte-
Hermann et al. 1993). Clear cell foci are thought to represent hepatocytes harbouring
the earliest ofpreneoplastic changes, mixed foci represent more advanced lesions,
whilst hyperplastic or hypercellular foci exhibit small cell change, and are thought to
be direct precursors of dysplastic nodules, which have a high probability of
undergoing neoplastic transformation (Sugitani et al. 1998;Terasaki et al. 1998).
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HCC are believed to develop from dysplastic hepatocytes that might be clustered in
small foci, or develop within cirrhotic nodules. HCC have been categorised as early
or late(Sakamoto et al. 1991). Early HCC may be very small, akin to a small focus
from which malignant cells proliferate, whereas advanced HCC is characterised by
rapid growth ofmalignant cells forming nodules which compress surrounding
structures. Early HCC are usually well differentiated and become poorly
differentiated as they invade locally and metastasize.
Behavioural characteristics of hepatocytes in chronic liver disease
As well as the characteristic cytological and histological changes that can be
commonly identified in the progression of HCC, there are a number of common
characteristics of chronically diseased liver which contribute to the emergence of
malignant clones. These include increased hepatocyte proliferation, increased
apoptosis and the development ofmonoclonal cell populations.
Increased Hepatocyte Turnover
Whereas hepatocytes normally proliferate slowly and are long-lived, chronic liver
disease is characterised by high rates of both hepatocyte proliferation and apoptosis,
which increase in parallel alongside morphological changes. In the disease-free state,
the liver is often described as quiescent. Typically, rates of hepatocyte proliferation
are extremely low with indices of 5-bromodeoxy-uridine (BrdU) incorporation of
less than 0.5% (Tarao et al. 1989). A number of markers of proliferation including
PCNA, Ki67 and BrdU, have been used to demonstrate a progressive increase in
rates of proliferation from cirrhosis through the development of FAH, dysplasia and
HCC (Coleman 2003;Grisham 2001a;Tarao et al. 1989). This increased proliferative
index correlates with increased risk for development of HCC (Ng et al. 1994) and
negatively correlates with patient survival (Borzio et al. 1998).
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Rates of apoptosis increase in parallel with increased rates of proliferation in
cirrhosis and chronic inflammation (Tannapfel et al. 1999). Increased rates of
apoptosis correlate with shorter disease-free survival in those with HCC (Ito et al.
1999a), although rates of proliferation persistently outstrip those of apoptosis
(National Institute of Health 2002;Park et al. 2001).
Development of monoclonal Hepatocyte populations
The development of monoclonal cell populations permits the accumulation of genetic
changes in continually proliferating cells. A highly sensitive method for determining
the clonality of hepatocytes is the demonstration of identical sites of HBV DNA
integration into the infected host hepatocyte. This method has been employed to
demonstrate monoclonal populations among non-tumorous preneoplastic hepatocytes
(Shafritz et al. 1981), cirrhotic nodules (Aoki et al. 1989), dysplastic nodules and in
tumours (Yamamoto et al. 1999).
Genetic Mechanisms of Hepatocarcinogenesis
Individual HCCs show considerable biological diversity, and much of the variation
in treatment outcomes and prognoses between individuals has been attributed to this
heterogeneity. Much interest has focused on attempts to find a common genetic and
mechanistic pathway linking HCCs that might provide a clearer insight into disease
progression, and therefore identifiy potential therapeutic targets. The development of
genetic profiling technology in the future may allow therapeutic strategies to be
based on individual tumour characteristics (Kim et al. 2003;Lee et al. 2005).
However, underlying the common morphological changes which occur during the
development ofHCCs there is undoubtedly an extremely complex interplay ofmany
different mechanisms that contribute to the development of the malignant phenotype
(Feitelson et al. 2002b). The predominant mechanism may be influenced by the
underlying aetiology, an obvious example being that of aflatoxin B1 exposure.
However, even within tumours grouped together by aetiology, the contributory
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influence of a particular mechanism may vary both between individuals and
temporally within the same tumour.
Chronic liver disease is, as already mentioned, characterised by hepatocyte damage,
necrosis and death. The monoclonal populations which emerge during the
development of HCC exhibit a selective advantage over their neighbours. This
results as a consequence of the random acquisition of genetic aberrations that, by
chance, confer a proliferative advantage. Such alterations are demonstrable in
preneoplastic lesions, with the severity of the lesions increasing in parallel with the
morphological changes. As a result of the random nature of these aberrations, both
genetic and epigenetic, clones which develop in diseased liver may share the
common characteristics of a mutant phenotype, such as deregulated proliferation, but
this common phenotype might result from alterations of very different pathways.
Genomic changes in preneoplastic liver
During the lengthy preneoplastic stage of the development ofHCC (which may last
for decades) changes in gene expression are brought about through epigenetic
mechanisms, rather than the structural alterations of genes or chromosomes seen later
in the development of this disease.
A characteristic of the preneoplastic phase of HCC development is the over-
expression of liver mitogens, the most important of which include IGF-2, HGF and
TGFa (Grisham 2001b). This increased expression is a consequence of a number of
factors including chronic inflammation resulting from continued liver damage, as
well as viral trans-activation and the regenerative response. Epigenetic mechanisms
also make a contribution. Re-imprinting of the IGF-2 gene and altered methylation
increase IGF-2 expression (Schwienbacher et al. 2000), resulting in the increased
production of this growth factor in the diseased liver.
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Further epigenetic changes associated with chronic hepatitis and cirrhosis include
aberrant methylation of CpG groups (Kanai et al. 2000). The activity ofDNA
methyltransferases (DNMTs), which catalyse the methylation and demethylation of
CpG groups, are increased in a proportion of cirrhotic and hepatitic livers (Saito et al.
2001), and greatly increased in HCCs (Lin et al. 2001;Tchou et al. 2000). Aberrant
methylation has been demonstrated in a number of genes and chromosomes for
example pl6INK4A, where it has been shown to correlate with decreased expression
in both HCC and cirrhosis (Kaneto et al. 2001). Aberrant methylation may not only
contribute to epigenetic gene expression, but may also predispose to genetic
instability through interaction of altered CpG sequences with chromatin,
predisposing to chromosomal breaks (Wong et al. 2001)
Microsatellite instability (MSi), thought to represent a mismatch repair deficiency,
has been demonstrated in some cases of chronic hepatitis and cirrhosis (Karachristos
et al. 1999), as well as in non-tumorous tissue adjacent to HCC (Salvucci et al.
1999). MSi can be demonstrated in approximately 25% of HCC in a pooled analysis
(Grisham 2001a).
Telomere shortening and increased telomerase activity have also been demonstrated
in preneoplastic hepatic nodules and in HCCs, suggesting these processes may be
important in the early development of the disease (Farazi et al. 2003;Kitamoto et al.
1999;Takaishi et al. 2000).
Further factors which may be of significance in the preneoplastic phase of HCC
include the cis- and trans-activation of host genes. This results as a consequence of
the direct integration of viral promoters into the host genome, as well as the
interaction of viral proteins, such as the hepatitis B protein (HBx), in regulatory cell
cycles. Such molecular events have the potential to alter the function of tumour
suppressors and oncogenes at this early stage (considered later, see Section
"Hepatitis Viruses in Liver Cancer")
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The potential survival benefit which may accrue in cell clones harbouring gene
mutations is amplified in an environment of continued proliferative pressure. Such
pressure is brought about by both the persistence of epigenetic changes producing
pro-proliferative growth signals, and the regenerative drive to replace dead
hepatocytes.
Structural genetic alterations develop slowly in the early preneoplastic phase, but
accelerate in dysplastic hepatocytes and HCCs. Ifmultiple loci are examined, allelic
deletions can be found in approximately 30-50% of livers with hepatitis, the majority
of livers with dysplastic nodules, and all HCCs (Thorgeirsson et al. 2002b). Identical
gene mutations have been demonstrated in dysplastic nodules and in adjacent HCCs,
suggesting HCCs may arise from the clonal expansion of such nodules (reviewed
(Grisham 2001a;Thorgeirsson et al. 2002a). Conversely, genetic aberrations in
preneoplastic tissue may differ from adjacent HCCs, suggesting that within
preneoplastic tissue there is a spectrum of mutations from which clones with a
particular advantage may expand to form HCC (Grisham 2001a;Roncalli et al. 2000).
The numbers of allelic deletions increase from a relatively low incidence in cirrhotic
liver, to a higher incidence in dysplastic nodules, and are highest in HCCs.(Buendia
2000).
Genomic changes in HCC
Nearly all HCCs show structural alterations in multiple genes and loci. Restriction
fraction length polymorphisms (RFLP) mapping has demonstrated recurrent allelic
losses and losses on many chromosomal arms. Polymerase chain reaction (PCR)
based studies have used microsatellites to determine loss of heterozygosity (LOH) in
HCCs with much greater sensitivity. Chromosomal aberrations appear to be more
common (occurring in >24% ofHCC) at chromosome arms l p, lq, 4q, 5q, 6q, 8p,
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9p, 13q, 16p, 16q and 17p (Coleman 2003). It is often accepted that loss of part of a
chromosome implies it harbours a tumour suppressor gene, which could potentially
lead to the identification of those genes that were critical in the progression ofHCC.
However, chromosomal alterations are not consistent between tumours and it is
unusual to find common specific alterations which affect more than half of analysed
HCCs (Thorgeirsson et al. 2002a). This variation persists even with strict
categorization according to tumour morphology, based on tumour size or histological
grade. Although some similarity exits when tumours are sorted according to
aetiological agents, such as the characteristic Ser 249 mutation of p53 that occurs
following AFB exposure, there remains a wide variation.
Hepatitis Viruses in Liver Cancer.
Infection with HBV and HCV is the commonest cause of liver cirrhosis and
ultimately HCC. Chronic hepatitis infection causes hepatocyte death, necrosis,
chronic inflammation and morphological, changes including cirrhosis. The relative
contribution of a number of factors, including viral infection, the immune response,
chronic inflammation, fibrosis and liver regeneration, to the development ofHCC is
extremely complex.
Hepatitis B
The World Health Organisation (WHO) estimate a third of the world's population
have been infected with HBV (World Health Organization 1996). Hepatitis B
accounts for 316,000 of the 530,000 cases ofHCC each year.(Lai et al. 2003). Those
with chronic HBV infection are 100 times more likely to develop HCC than
uninfected individuals (Chu 2000). HBV is a partially double stranded hepadna virus.
The HBV genome encodes for a number of proteins including those for a reverse
transcriptase, an envelope protein and the HBx protein.
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The mechanisms through which chronic Hepatitis B infection brings about the
development ofHCC are not yet fully understood. Certainly chronic infection seems
to be linked to the perturbation of a myriad of cellular processes and regulatory
networks. The mechanisms through which the virus effects these changes can be
grouped under the following four headings.
• Chronic Inflammation
• Physical integration of the viral genome causing structural host
genomic changes
• Functional integration of the viral genome causing aberrant gene
expression
• Expression of the viral genome and transcription of viral proteins,
predominantly HBx
Chronic Inflammation
The expression of viral proteins by infected hepatocytes induces a cytotoxic T
lymphocyte (CTL) mediated immune response with immune mediated destruction of
hepatocytes through apoptosis. The downstream inflammatory cascade results in
inflammatory liver disease and liver necrosis. There is a pro inflammatory cytokine
milieu, characterised by increased levels of cytokines such as TNFa and IL2. (Diao
et al. 2001)) This pro-proliferative environment itselfmay be sufficient in a chronic
setting to promote the development of HCC, through a combination of sustained
mutagenesis and regeneration. This hypothesis has been supported by the finding that
the immune response to transgenic expression ofHBV surface antigen alone is
sufficient to cause necro-inflammatory disease and HCC (Nakamoto et al. 1998).
Attenuation of this immune response by inhibiting T cell mediated apoptosis through
the neutralization of Fas ligand is sufficient to prevent the development ofHCC in
this model (Nakamoto et al. 2002).
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Integration of the viral genome causing structural host genomic changes
Integration of the Hepatitis B genome is not required for the successful replication of
the virus. This integration is random, and does not preserve the viral genome
sequence. Therefore, the integrated sequence is insufficient to function as a template
for viral replication. HBV DNA sequences have been identified in liver tissue both in
cirrhotic patients with chronic hepatitis and in HCC (Brechot et al. 1980). Integration
of the viral genome has been demonstrated early in the course of infection
(Murakami et al. 2004) and can bring about structural chromosomal instability by
inducing chromosomal deletions at the integration site, as well as translocations from
one chromosome to another (Pineau et al. 1996). Such random chromosomal
alteration could lead to the loss of function of genes essential to cell cycle control,
differentiation or apoptosis (Staib et al. 2003b).
Functional Integration of the viral genome causing aberrant gene expression
The extent to which HBV genome integration can bring about transactivation of
cellular genes is still debated. There are very few examples of the integration ofHBV
DNA within, or near, known human genes. In the experimental woodchuck model of
hepatitis (WHV), insertion of the WHV genome has been frequently found in the c-
myc oncogene (Jacob et al. 2004), though in human HCC integration of the HBV
genome into known oncogenes is thought to be a rare event. There is sporadic
evidence to suggest HBV integration can occur in genes important to the control of
cell signalling, such as steroid receptors (de The et al. 1987), in genes controlling
proliferation (Wang et al. 1990), and in genes contributing to chromosomal
instability, such as those for telomerases (Brechot 2004a;Paterlini-Brechot et al.
2003). However these reports are exceptions and HBV DNA integration into known
cellular genes appears to occur so infrequently it is unlikely to be a major factor in
the development ofHCC.
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Expression of the viral genome and the transcription of viral proteins, predominantly
HBx
Many of the cellular effects of chronic viral infection are thought to be mediated
through the expression of the HBx protein. The HBx protein can act as a
transcriptional transactivator of a number of different cellular genes associated with
the control of proliferation. It is named the "X" gene because its role in terms of the
life cycle of the virus was initially unclear. Loss of the HBx gene from the
woodchuck hepatitis virus results in the virus being unable to sustain chronic
infection in the host (Zoulim et al. 1994), therefore suggesting a role in the
pathogenesis of chronic infection. The HBx viral genome is the most commonly
found portion of the viral genome found in HCC (Paterlini et al. 1995), and
expression of HBx protein increases with the development of cirrhosis and is very
common in HCC (Wang et al. 1991). High levels ofHBx expression in both cirrhotic
patients and in HCC suggests this protein may play an active role in the pathogenesis
ofHCC.
The evidence from transgenic mouse studies is not straightforward. Although over-
expression ofHBx in a mouse model on a CD1 background is associated with the
development ofHCC, the results are not consistent between strains and appear to be
dependent on both the level ofHBx expression and the genetic background of the
mice (Kim et al. 1991;Koike et al. 1994;Yu et al. 1999). HBx expression on
backgrounds other than CD1 does not necessarily lead directly to HCC, but sensitises
mice to DEN (Slagle et al. 1996) and c-myc induced malignancies (Terradillos et al.
1997).
HBx has no direct DNA binding activity, but has been demonstrated to modulate the
expression ofmany target genes through protein-protein interactions (Brechot
2004b;Feitelson et al. 2005).
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Microarray studies have shown HBx expression in hepatoma cells can up- or down-
regulate the expression of a large raft of genes which could contribute to Hepatitis B
pathogenesis (Ng et al. 2004). Potentially important, though still controversial, roles
HBx may play in the pathogenesis of HCC include modulation of proteasome
function, mitochondrial interactions, and modulation of calcium homeostasis.
The potential effects HBx may play on cell cycle regulation, apoptosis and
hepatocarcinogenesis through its affects on the p53 and Rb pathways will be
discussed in the sections "Disruption of the Rb/E2F pathway in Hepatocellular
Carcinoma" and "Disruption of the ARF-MDMD2-p53 pathway in Hepatocellular
Carcinoma".
Hepatitis C Virus
Hepatitis C infection is now the leading cause of viral hepatitis, liver cirrhosis and
HCC worldwide, and its incidence, particularly in the west, is increasing (National
Institute of Health 2002). HCV is a single stranded RNA flavivirus whose infection
of the liver is associated with greater levels of cirrhosis compared to those ofHBV
infection (70% vs. 50%), and of these cirrhotics a greater fraction will develop HCC
(75% vs. 29%) (Ikeda et al. 1993). The HCV RNA genome encodes a polyprotein
which is processed by viral and cellular proteases into a core protein, two envelope
proteins, El and E2, and several non-structural proteins. Constitutive expression of
the HCV core protein produces HCC in mice, particularly on a background of
chronic inflammation (Kato et al. 2003). HCV core protein has been demonstrated to
interact with a number of host regulatory pathways including cell signalling,
transcriptional modulation, transformation, and translational regulation
(Tellinghuisen et al. 2002). However, the relevance of these interactions to human
disease has not been convincingly demonstrated.
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Aflatoxin B1 in Liver Cancer
Aflatoxin is a fungal metabolite produced by Aspergillus flavus. Metabolites of
aflatoxin B1 (AFB1) can cause DNA damage. The base guanine (G) is particularly
susceptible to AFB1-induced damage, and this characteristically results in a guanine:
cystine to thymidine: adenine (GC-»TA) transversion. HCCs which develop in
individuals with a high exposure to AFB1 (such as southern Africa and the Qigong
area ofChina) exhibit this specific mutation at codon 249 of the p53 gene. This
specific mutation of p53 is rare in areas where the exposure to AFB1 is low,
suggesting this mutation may be unique to AFB 1-induced HCCs. Epidemiological
evidence has been supported by experiments demonstrating AFB 1 exposure can
produce this characteristic mutation both in vitro and in vivo (reviewed (Smela et al.
2001). The intake of AFB1 is proportional to the p53 mutational load and aflatoxin
exposure concomitant with hepatitis B infection increases the risk of HCC,
suggesting a synergism between these two aetiological factors (Ming et al. 2002;Sun
et al. 1999).
Disruption of the Rb/E2F pathway in Hepatocellular Carcinoma
As already discussed, disruption of the Rb pathway is deemed essential for the
development of cancer (Hanahan et al. 2000). Which component of the pathway is
disrupted varies somewhat between tumours, depending on their biological
heterogeneity, but it would appear that where the composite members of the Rb
pathway are examined in individual HCCs, it is possible to demonstrate the loss of
function of one such member in the majority of cases (Azechi et al. 2001 ;Edamoto et
al. 2003).
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Cyclins D and E
Amplification of the Cyclin D1 gene and over-expression of Cyclin D1 protein is a
common finding in HCCs, and is associated with a more aggressive tumour
phenotype and shortened disease-free survival (Azechi et al. 2001;Edamoto et al.
2003;Ito et al. 1998;Ito et al. 1999a;Nishida et al. 1994).
Over-expression of Cyclin E has been demonstrated in both HCCs (Ito et al. 1999a),
and in adjacent non-tumorous tissue. (Peng et al. 1998).
These finding of increased cyclin levels in human HCCs are in keeping with
observations from animal models. Transient over-expression of Cyclin D1 in mice
using an adenoviral delivery system is sufficient to induce DNA synthesis, mitosis
and liver enlargement (Nelsen et al. 2001b). Constitutive over-expression of Cyclin
D1 in transgenic mice results in dysplastic change in the liver, with adenomas
appearing at 9 months and progression to HCC over the ensuing 6 months (Deane et
al. 2001). Similarly, transfection of hepatocytes in vivo with Cyclin E in
combination with skp2 causes hepatocyte replication and liver hyperplasia (Nelsen et
al. 2001a).
The CIP/KIP family
Mutations of the CIP/KIP family are unusual in human tumours (Shiohara et al.
1994), although low expression of p27 is associated with a less favourable prognosis
in breast tumours (Barnes et al. 2003). Down-regulation of p21 has been
demonstrated in HCC, but this is generally in conjunction with, and thought to be a
consequence of, p53 loss. (Hui et al. 1997)
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Interestingly, HBx transcriptionally down-regulates p21 expression through both p53-
dependent (Wang et al. 1994) and p53-independent mechanisms(Ahn et al. 2001),
resulting in increased hepatocyte proliferation. Similarly, the HCV non-structural
protein, NS5A, suppresses the transcription of p21 in HepG2 (Human hepatocellular
liver carcinoma cell line) cells (Ghosh et al. 1999). Co-expression ofHBV and HCV
proteins in a hepatocyte cell line results in co-repression of p21 activity (Han et al.
2002;Peng et al. 1998). Typical of the multiplicity of effects ofHBx, its effect on
p21 expression seems to be determined to a degree by the system in which it is
examined, and by which natural HBx variant is examined (Kwun et al. 2004).
The INK4a-Family
In contrast to the CIP/KIP family, mutations in the INK4 family, particularly
pl6INK4a, are much more commonly implicated in the aetiology of human cancer
(reviewed (Ortega et al. 2002). A number of studies have demonstrated complete loss
of the pl6INK4a protein in HCC (Hui et al. 1996;Jin et al. 2000). This loss of
expression is associated with high rates of gene methylation (Matsuda et al.
1999;Ortega et al. 2002), although gene deletion has also been described (Biden et al.
1997;Liew et al. 1999). Interestingly, germ line mutations of the pl6INK4a gene
have been identified in a small percentage of HCC. (Chaubert et al. 1997) Those
patients which carry the germ line mutation develop HCC at a relatively early age in
the absence of cirrhosis.
pRb
Lack of pRb expression is a common finding in HCC, occurring in 54% in pooled
studies (Grisham 2001a). Loss of expression correlates closely with allelic deletion.
The frequency of LOH varies from 10% (Nakamura et al. 1991) to 73%(Ashida et al.
1997), and in accumulated studies in one exhaustive review (Grisham 2001a),
represents 32% of sampled HCCs.
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LOH of Rb has also been demonstrated in cirrhotic nodules adjacent to HCCs, with
the same alleles lost in both cases. In the same study Rb was maintained in HCCs
whose nearby cirrhotic nodules also retained Rb. Such a finding suggests HCC may
develop from cirrhotic tissue in which Rb loss could be an early transforming event.
Supportive evidence for a potential role for loss of Rb function as an early event in
hepatocarcinogenesis, comes from in vitro observations that HBx can abrogate the
repressive activity of pRb (Sirma et al. 1999a). However, such a conclusion is not
supported by other studies that demonstrate Rb is retained in cirrhotic tissue
surrounding HCCs where LOH of Rb can be demonstrated (Kuroki et al. 1995).
Futhermore, allelic loss of Rb occurs only in advanced or poorly differentiated
HCCs, rather than early, well differentiated tumours (Murakami et al. 1991;Zhang et
al. 1994).
E2F
Neither mutation nor deletion of E2F1 have been identified in HCCs, nor indeed in a
spectrum of other human tumours (Nakamura et al. 1996).
63
Disruption of the ARF-MDMD2-p53 pathway in Hepatocellular Carcinoma
p53
As mentioned already, acute Rb loss causes p53 stabilisation and increased
apoptosis. This has important implications for incipient tumour cells which may have
a deregulated Rb pathway. If the mechanisms for p53 stabilisation are intact, the cell
will be directed towards cell cycle arrest or death. Evasion of apoptosis is an
important hallmark of cancer, allowing the incipient cancer cell to escape death.
p53 is a homo-tetramer transcription factor which responds to a number of cellular
stresses including irradiation, hypoxia, genotoxic activation and oncogene activation
(Giaccia et al. 1998;Levine 1997). p53 may effect two quite different outcomes to
such stimuli, either countering cell proliferation by inducing cell cycle arrest, or
inducing cell death through apoptosis. Lesser members of the same family include
p73 and p63 (reviewed (Sherr 2004).
Similarly to Rb, loss of p53 function is considered an obligatory step in tumour
development, and it is one of the most frequently mutated genes in human cancer. As
disruption ofpRb function may be brought about by loss of function, or increased
activity, of one part of the Rb pathway, similarly loss of function of p53 may be
brought about through disruption of some part of the p53 pathway, primarily that of
the ARF-MDM2-p53 axis.
ARF deficient mice exhibit a high tumour burden, particularly lymphomas and
sarcomas, and die early in life, although they do not develop liver tumours (Kamijo
et al. 1999). The ARF gene is methylated in a proportion ofHCCs (Edamoto et al.
2003;Tannapfel et al. 2001), and interestingly, loss of ARF is inversely correlated
with loss of p53, suggesting that loss of p53 and ARF are mutually exclusive events.
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Increased expression ofHDM2 is a commonly found feature of a large number of
solid human tumours (reviewed (Rayburn et al. 2005). A high level MDM2
expression is a feature of preneoplastic foci in DEN-induced rodent models of liver
cancer, where it is associated with reduced p53 function (Van Gijssel et al. 2000),
and increased expression of HDM2 has been observed in regenerative nodules in
cirrhotic liver (Schlott et al. 2002). Over-expression ofMDM2 has also been
demonstrated in a significant proportion ofHCCs and correlates with reduced
survival (Endo et al. 2000).
Mutation of p53 occurs in approximately a third ofHCCs, although the frequency of
mutations varies between different geographical regions. As already mentioned,
exposure to the carcinogen, AFB1, produces a characteristic p53 mutation which
accounts for the higher rates of p53 mutation seen in Africa and China compared to
the West (Staib et al. 2003a). In addition to the characteristic mutation seen
following AFB1 exposure, over 75 mutations have been demonstrated in the p53
gene in different HCCs (Staib et al. 2003a). The resultant p53 mutant proteins confer
a proliferative advantage to hepatocytes.
Attempts to model the effect of p53 loss in the development of HCC in mouse
models of the disease are confounded by the fact that mice homozygous for p53
deletion die from lymphomas within 6 months (Purdie et al. 1994) and so are
unsuitable for long term hepatocarcinogenesis experiments. However, using mice
which are heterozygous for p53, models have demonstrated that along with male sex,
AFB1 exposure and hepatitis B surface antigen (HbsAg) exposure, p53 is an
independent risk factor for the development ofHCC in such models. Combinations
of these factors are synergistic in the development ofHCCs, which mirrors the
synergy of risk factors seen in the human disease (Sell 2003b).
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HBx and p53.
Studies investigating the pathobiological effect of the HBx protein have
demonstrated that it binds to, and inactivates, p53 (Elmore et al. 1997;Ueda et al.
1995;Wang et al. 1994;Wang et al. 1995). This deregulates cell cycle check point
controls and blocks p53 mediated apoptosis (Feitelson et al. 2005). This amelioration
of the apoptotic abilities of p53 may provide a selective advantage for incipient
neoplastic hepatocytes. Transfection of primary hepatocytes with HBx using an
adenoviral vector followed by subsequent array analysis reveals that a host of
transcripts are up-regulated in transfected cells compared to control cells, suggesting
that HBx may effect gross changes in a large array of cellular pathways either
through, or independently of, its effects on p53 (Feitelson et al. 2005;Wu et al. 2002).
HCV and p53
Much less is known of the mechanisms of action of HCV proteins compared to HBx,
although in specific reference to p53, some evidence suggests the HCV protein, NS3,
binds to and transcriptionally represses the p53 promoter (Ray et al. 1997). There is a
comparatively much lower rate ofmutation of p53 in HCV compared to HBV
infection, suggesting that in HCV functional inactivation may be more important
than selection for mutation in escape from apoptotic control.
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Section E. Conditional Models of Gene Deletion
Conditional gene targeting allows the temporal and tissue-specific inactivation of
genes whose deletion through conventional gene targeting strategies leads to
embryonic lethality. The more commonly used of the available systems is that of
Cre/Lox technology. Cyclization recombination (Cre) is an Escherichia coli
bacteriophage PI enzyme expressed during virus replication. It recognises a
palindromic sequence on the PI genome known as locus of crossover ofPl(LoxP).
The Lox P sequence comprises two identical 13 base pair (bp) regions either side of a
non-palindromic core that confers directionality. Each 13 bp sequence binds a single
Cre molecule. Depending on the orientation of LoxP sites, Cre can either invert or
excise the portion of interposing DNA.
The Cre/Lox system has been used extensively in many tissues to bring about
conditional gene targeting. Such tissue specific knockouts have been used to examine
the effect of Rb loss in vivo in the lung (Meuwissen et al. 2003), pituitary gland
(Vooijs et al. 2002), ovary (Flesken-Nikitin et al. 2003) and mid brain (Marino et al.
2000).
Summary of Introduction
In the healthy liver hepatocytes are quiescent, and replicate only very slowly.
However, when the liver is damaged liver regeneration results in the rapid restoration
of liver mass through a strictly regulated proliferative response. This is associated
with an increase in polyploidisation in the liver, the significance of which remains
unknown. In chronic injury, as seen in Hepatitis infection, there is on going
hepatocyte death and regeneration which precedes the development of liver cancer.
The Retinoblastoma gene, a prototypic tumour suppressor, has been ascribed a
fundamental role in the control of cell replication and the suppression of
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carcinogenesis in all organs. Current evidence suggests the function ofRb may be
affected both directly and indirectly by Hepatitis infection, and that loss of function
of the Rb pathway occurs in the development of liver tumours. The role of Rb has
not been previously demonstrated in either the regulation of liver regeneration and
polyploidisation, nor has the loss of function ofRb in the development of liver
cancer been examined.
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Chapter 2 Hypothesis and Aims
Hypothesis
Loss of Rb function will de-regulate the processes of liver regeration and
polyploidisation, predisposing to the development of liver cancer.
Aims
1. To establish in vivo recombination of a floxed Rb gene using an
adenoviral Cre delivery system.
2. To establish two models of liver regeneration, surgical (PH) and toxic
(CCL4).
3. To determine the role of Rb in the processes of hepatocyte proliferation
and polyploidisation by using a system of conditional Rb loss in the two
models of regeneration
4. To determine the effect ofRb loss on the preneoplastic development of
HCC using the system of conditional Rb loss in a chemical model of
hepatocarcinogenesis (DEN).
5. To determine the effect of the loss of p53 in combination with that of Rb





Bromodeoxyuridine (BrdU; Amersham Biosciences RPN 201) was injected into the
peritoneal cavity at a dose of 10 pig"1 2 hours prior to culling. At culling, the liver
was removed and fixed in cold, freshly prepared methocarn (60% methanol; 30%
chloroform; 10% acetic acid). The tissue was fixed (4 °C; overnight) prior to
processing and mounting in paraffin. Tissue sections of 4 pM were cut onto BDH
SuperFrost® Plus glass slides (Cat no 406/0179/00) and dried (37 °C; overnight).
The sections were hydrated by washing in xylene (5 min) and graded alcohols
through to double distilled water (ddfUO). The slides were then incubated in
hydrochloric acid (HC1; 5M) for 45 min, before repeated washing in PBS (5mins;
x3). Following this, the slides were incubated (10 min) in H2O2 (1%) to block
endogenous peroxidase activity, and then washed twice in PBS (5 mins). Slides were
then incubated (10 mins; room temperature) in blocking solution (PBS containing
normal rat serum (20%) plus Tween 20(0.05%)). Slides were then drained and
incubated (1 hr; room temperature) in rat anti-BrdU antibody (Oxford Biotechnology
cat no OBT 0030) diluted 1:100 in blocking solution. After repeated washing in PBS
(5 min; x3) the slides were incubated (30 min; room temperature) with rabbit anti-rat,
horse radish peroxidase conjugate (Sigma product no A5795) diluted 1:100 in
blocking solution. After three further washes the slides were incubated (15 mins;
room temperature) in diaminobenzidine (DAKO cat no K3467) and washed in
ddH20. Sections were counterstained with Harris haematoxylin, and then dehydrated
through graded alcohols to xylene. The slides were mounted using pertex.
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PCNA Immunohistochemistry
Tissue sections were prepared as above. The sections were hydrated after washing in
xylene (5 min) and graded alcohols through to ddH20. The slides were then
microwaved (10 mins) at full power in Vector Antigen Unmasking Solution (cat no
H-3300), and then allowed to cool to room temperature. The slides were repeatedly
washed in ddH20 (x3) and then washed once in PBS. The slides were then incubated
(10 min; room temperature) in H2O2 (3%) to block any endogenous peroxidase
activity and then repeatedly washed in PBS (x3). Slides were then incubated (10
min) in Vector Avidin block solution, followed by repeated washing in PBS (x3),
and incubation (10 mins) with Biotin Block solution (both from the Vector Avidin
Biotin Blocking Kit cat no SP-2001). The slides were then incubated (10 min) in
DAKO Protein Free Serum Block (cat no X0909). The primary mouse anti-PCNA
biotin conjugated antibody (Ebiosciences cat no 13-9910) was diluted to 1:100 in
DAKO Ready-to-use diluent (cat no S0809) and incubated with the slides (1 hr;
room temperature). The slides were then washed repeatedly in PBS (x3) and
incubated (15 mins) with Vector ABC Stain Kit (Kit PK-4000). Finally, the slides
were washed thoroughly in water, counterstained (1 min) with Harris Haematoxylin
and then dehydrated through graded alcohols to xylene. The slides were mounted
using pertex.
Ki67 Immunohistochemistry
Tissue sections were prepared as above and antigen retrieval was performed as
described for the PCNA immunohistochemistry. Following incubation in Protein
Free Serum Block (DAKO), the monoclonal primary rat anti-mouse Ki67 antibody
(DAKO Ki67 Clone TEC-3, Code no M7249) was diluted to 1:25 in DAKO Ready-
to-use diluent (cat no S0809) and incubated with the slides for 2 hours at room
temperature. The slides were then washed in PBS (x3) and incubated with rabbit anti
rat secondary antibody rabbit anti-rat, horse radish peroxidase conjugate (Sigma)
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diluted 1:100 in ChemMate (DAKO) for 2 hours at room temperature. After washing
(PBS, x3), slides were incubated (15 min)with diaminobenzidine (DAKO), then
washed in ddH20. Sections were then counterstained with Harris haematoxylin, prior
to dehydratation through graded alcohols to xylene. The slides were mounted using
pertex.
Flow Cytometry
Using a 1ml syringe and a 23G needle, a gentle fine needle aspirate (FNA) was
extracted from fresh mouse liver. The aspirate was then gently flushed into a sterile
1.5 ml eppendorf, immediately snap frozen in liquid nitrogen, and stored (-80°C)
until analysis. Analysis was carried out as soon as possible (typically within 1
month) as there was notable sample deterioration following prolonged storage, even
at -80°C (Vindelov et al. 1983a). To prepare the aspirate for determination of nuclear
ploidy, a standard Vindelov preparation was used as described below (Vindelov et al.
1983b). Composition of the buffers used is given in the Appendix. Samples were
defrosted at room temperature before microcentrifugation (4000 rpm; 4 mins). The
citrate buffer supernatant was carefully aspirated and 450 pi of Vindelov A solution
added to the cell pellet, which was re-suspended by tapping the tube gently on the
bench top. The cell pellet was then incubated with the Vindelov A solution for 10
minutes on a rocker at room temperature. Following this 10 minute incubation, 325
pi ofVindelov B was added to the tube before a second incubation of 10 minutes on
a rocker at room temperature. Following this 10 minute incubation, 250 pi of
Vindelov C solution was added to the tube and the sample incubated for 10 minutes
on a rocker at room temperature, protected from light. Following this final
incubation, the sample was placed on ice and analysed by flow cytometry as soon as
possible (typically within 1 hour). Flow cytometric analysis was performed using a
Coulter®Epics®XL Flow Cytometer (Beckman Coulter Electronics). A maximum of
10 samples were analysed on each occasion. Immediately prior to flow cytometric
analysis, the sample was passed through a 100 pm cell strainer (Becton Dickson) to
remove any potentially undigested material. Propidium iodide (PI) was excited in
488 nm argon laser light and the emitted fluorescence was detected at 620 nm. The
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stochiometric binding of PI to DNA means nuclear fluorescence is directly
proportional to DNA content. The percentage of 2n, 4n, 8n and 16n nuclei were
expressed as a percentage of the sum of the total gated events.
On each occasion, prior to analysis of each batch ofmouse liver samples by flow
cytometry, a control sample of adult chicken cells (TCS Biosciences Ltd Ref FB010)
was analysed to act as a reference point for the relationship between DNA content
and absolute fluorescence. 45 pi of adult chicken cells were added to 95 pi of PBS.





Partial hepatectomy (PH) in the rat was first described by Higgins and Anderson in
1931 (Higgins et al. 193la). The technique for PH in the rat has been well described,
both in the original Higgins manuscript and in addition specialised texts (Waynforth
et al. 1992) (Figure 7, below). Although the procedure ofPH in the mouse appears
relatively frequently in the literature, the actual technique used is rarely accurately
described. The anatomy of the rat liver varies considerably from that of the mouse;
specifically in its peritoneal attachments and anatomy of the biliary tree (the mouse
has a gallbladder whilst the rat does not). Therefore, it was necessary to adapt the
technique of PH described for the rat in order to be able to perform it safely in the
mouse.
Figure 7. Established surgical approach to PH in the rat showing the lobes of the liver
prolapsed through a midline incision. (Waynforth et al. 1992)
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Surgical Approach
As shown in Figure 7, the established surgical approach to the rat liver is via a
midline abdominal incision. Gentle abdominal pressure is sufficient to deliver the
lobes of the liver through this wound. The desired lobes of the liver can then be
picked up, ligated and excised. This technique is not appropriate for the mouse for a
number of reasons; the abdominal wall in the mouse is much thinner and although
pressure on the abdomen will deliver the lobes of the liver through the wound, there
is insufficient tension around the edges of the wound to hold the prolapsed liver
lobes out of the peritoneal cavity. In addition, the mouse liver is extremely delicate
and traction on the peritoneal attachments of the liver is sufficient to cause bleeding
from the liver capsule, which can be irretrievable. Although this technique has been
employed for PH in the mouse by some groups in the UK, it was felt necessary to
make a number of adaptations in an effort to overcome some of the limitations
described above. The technique of PH is illustrated in Figure 8a-r from page 77. In
terms of the surgical approach, a bilateral sub-costal "roof top" abdominal incision
was adopted because it gives excellent access to, and exposure of, the liver,
particularly when the mouse is positioned over a bolster. One potential drawback of
this approach is bleeding from the anterior abdominal wall, which looks trivial but
can be significant given the average blood volume of a mouse is 2 ml. In order to
avoid this problem, the superior epigastric vessels were routinely ligated before
incising the abdominal musculature (Figure 8e). The excellent exposure afforded by
the bilateral subcostal approach allowed mobilisation of each of the liver lobes by
division of their peritoneal attachments. This was important because it allowed the
ligatures to be placed close to the pedicle of each lobe. Additionaly, it reduced the
possibility of such ligaments causing bleeding at their attachments to the liver during
retraction. The rat liver does not contain a gallbladder whilst in the mouse the
gallbladder is located at the sulcus between the left and right portions of the median
lobe. It was therefore necessary to excise the median lobe of the liver in two sections,
thus leaving the gallbladder in it native position. The closure of the subcostal wound
is straightforward and the skin heals very well (Figure 8r). Skin clips can be removed
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10 days post surgery. Figure 9 (page 80) demonstrates the hyperplasia which
in the residual liver lobes following 2/3 PH.
Technique of partial hepatectomy in the mouse
a. The mouse is positioned in the supine position with a 1 ml syringe providing a bolster to produce
extension.The limbs are secured such that the mouse inclined with the head higher than the tail
b, c The xiphisternum is easily palpable A transverse incision is made in the skin just beneath the
xiphisternum and this extended interiorly and laterally to produce a bilateral subcostal incision
d. The musculature of the anterior abdominal wall is incised in the midline to create a
pneumoperitoneum
e. The superior epigastric vessels are ligated in continuity using a 5/0 silk suture (arrows)
f. g The incision is then extended laterally on each side.The inferior flap of the wound tends to fall
away to give excellent views of the liver
1 .Falciform ligament 2.Gall bladder
3.Left lobe of the liver 4.Two parts of the median lobe of the liver
Figure 8
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h. The peritoneal attachments of the left lobe are divided and the lobe is gently retracted to the left.
A loop of silk suture is manoeuvred around the lobe and tied at its narrow pedicle.
i. Upon tying the lobe immediately becomes dusky, it is then excised, leaving just a small remnant (j)
k. A second ligature is manoeuvred around the right part of the median lobe.
Care is taken to avoid both the gall bladder and the common bile duct.
I,m The ligature is carefully tightened, taking care not to include the right lobe which sits interiorly




n A third ligature is placed around the left portion of the median lobe, tied and the lobe is excised (o)
p The abdominal wall is closed using continous 5/0 silk suture.The skin is closed using skin clips,
q The mouse is allowed to recover until it is mobile on thewarming operating pad then returned
to a warming cabinet
10 days following the procedure wound clips can be removed,
thewound heals very well
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Figure 9. Photograph demonstrating the hyperplasia of the residual lobes of the liver
which occurs following PH. The liver on the left of the photograph from a non
operated animal shows the anterior (AR) and posterior (PR) lobes of the right liver
lobe along with caudate (C) lobes, which make up the remnant of the liver following
PH. The liver on the right of the photograph shows the same lobes of the liver from a
littermate of the same size, 10 days following a 2/3 PH. In each case the liver has been
fixed in methocarn.
Anaesthesia for Surgery
Isofluorane inhalational anaesthesia, as opposed to injectable anaesthesic agents
which are often used in rodents, was found to be preferable for a number of reasons:
1. Inhalational anaesthesia allows the depth of anaesthesia to be varied
throughout the procedure. This is important as it became apparent that the
depth of anaesthesia increased with the length of the procedure. This may be
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because of slight decreases in the mouse core temperature and hence,
decreases in the metabolism of the anaesthetic agent.
2. Upon completion of the procedure, anaesthesia can immediately be
withdrawn and the animal recovered, avoiding the potential complications of
prolonged anaesthesia, such as hypovolaemia and hypothermia.
3. Injectable anaesthetic agents are often metabolised in the liver and following
partial hepatectomy there is the obvious concern of reduced liver function.
Isofluorane was used rather than halothane, which can be hepatotoxic in the mouse
as well as the human.
Analgesia, Fluid Replacement and Temperature Homeostasis
The opiate, buprenorphine, was chosen for peri operative analgesia - a non-steroidal
agent would be contraindicated in the presence of liver insufficiency. It was found
preferable to give buprenorphine subcutaneously at the beginning of the procedure
because giving analgesia at this point meant that on recovery the opiate was already
in the circulation, removing the potential for the mouse to experience pain during
recovery before analgesia can be given. Buprenorphine was given at a dose of 0.05 -
1 mg.kg"1 subcutaneously.
Hypoglycaemia is a common complication of total hepatectomy in the rat, though it
would not be expected to be a problem following resection of 2/3 of the liver mass
because the gluconeogenic activity of the liver remnant is up-regulated rapidly
following surgery. However, recovery following surgery appeared to be improved
when mice were given a bolus ofwarmed dextrose saline, as opposed to normal
physiological saline solution. A bolus of approximately 0.75 - 1.0 ml of dextrose
saline (NaCl 0.18%, dextrose 4%) was given both at induction, and at completion, of
the procedure.
In the post-operative period animals were observed very closely in the hours
following surgery and routinely on the following days. If animals did not quickly
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return to normal activities, further doses of of analgesia and/or subcutaneous fluids
were administered.
During the procedure, the animals' core temperature was maintained using a
warming blanket (Harvard Apparatus). These specialized devices automatically
adjust the heat output of the blanket in response to the animal's temperature, which is
measured using a rectal thermometer. Following recovery, animals were all routinely
kept overnight in individual, humidified warming chambers maintained at 28 °C,
with free access to water and mash. They were then returned to individual, standard
caging on the first post-operative day.
Mortality Following Surgery
The mortality following 2/3 PH is shown in Figure 10. Mortality is expressed using
cumulative summation methodology (CUSUM) (Bolsin et al. 2000). This allows the
mortality for a procedure to be assessed against an acceptable standard, in this case
10%, which was the mortality limit agreed in the Home Office licensing for this
project. From procedure 50 onwards, there is clearly a rapid improvement in
mortality. The overall post operative mortality for the procedure was 6.7% (n=194).
Mortality for the first 50 procedures was 18% and for the next 144 procedures was
2.7%. This probably reflects a number of factors including refinement of surgical
techniques and equipment, improved peri operative care, and possibly improved
overall health of the animals following their-derivation and re-housing of the colony.
This process began at approximately procedure number 54.
Further factors that may have affected mortality are shown in Table 1. Interestingly,
all of the mice that received viral treatment survived. This may be related to some
sort of non-specific pre-conditioning effect, though as the percentage of deaths is
relatively small, it is difficult to draw any firm conclusions from this observation.
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Table 1. Contingency table illustrating the characteristics of those mice that survived
or died following 2/3 PH.
Total Age
(days)
Sex Genotype Virus Treatment









Survived 181 67 94 87 111 14 48 14 64 29 88
Dead 13 66 5 8 6 0 7 0 0 0 13
Percentages
Survived 93.3% 94.9% 91.6% 94.9% 100.0% 87.3% 100.0% 100.0% 100.0% 87.1%
Dead 6.7% 5.1% 8.4% 5.1% 0.0% 12.7% 0.0% 0.0% 0.0% 12.9%
Figure 10. CUSUM survival chart showing change in operative mortality against
procedure number for 2/3 PH. The formula for CUSUM is Sk = SUM(XBar - T) where X is
the mean survival from each group and T is the target percentage survival.
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Animal treatment with Diethylnitrosamine
14-day-old mouse pups were injected intra-peritoneally using a 50 pi glass gas
chromatography syringe (Syringe SGE 004232; Fisher Scientific) with a single dose
(50 mg.kg'1) ofN-Nitrosodiethylamine (DEN; Sigma Aldrich) freshly prepared by
dilution in filter-sterilised PBS.
Treatment with Carbon Tetrachloride
Carbon Tetrachloride (CC14; Sigma Aldrich) was diluted in freshly prepared filter-
sterilised olive oil (Sigma) to a concentration of either 2.5% for chronic
administration in the carcinogenesis protocol, or 10% for regeneration experiments.
The solution was freshly prepared in glass and vortexed vigorously prior to each
injection using a 500 pi glass gas chromatography luer lock syringe (Syringe SGE
005230; Fisher Scientific). A dose of 10 pi of the CC14 solution was given per gram
of animal body weight. Figures 11 and figure 12d (page 86) respectively show the
histological and macroscopic appearance of the liver 24 hours following the injection
of a single dose of CC14 at a volume of 10 pi per gram body weight.
Figure 11. An H&E stained liver section showing typical centrilobular necrosis 24
hours following a single dose of CCI4. The vascular structures in this section have
been filled with white for the purposes of quantifying the percentage of necrosis on
the section. (Magnification x50)
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Injection of Adenovirus
The desired amount of virus was prepared in sterile PBS to a volume of 100 pi. Prior
to injection, each animal was warmed in a commercial warming device at 35 °C for
no more than 10 minutes. Continuous careful inspection was essential to avoid
causing distress or inadvertent dehydration to the animal. The mouse was then
restrained in a commercially produced, small animal plunger-type restrainer
(Braintree Scientific Inc., Braintree, Massachusetts) and injected via the lateral tail
vein using a 29 gauge, 0.5 ml insulin syringe (Becton Dickson Micro Fine+ ). Great
care was taken to avoid inadvertently injecting air into the vein by fastidiously
removing all air bubbles prior to injection. Successful injection can be determined by
observation of general, rather than localised, blanching of the tail and the absence of
resistance to depression of the plunger. Subcutaneous injection is quite apparent due
to obvious local swelling and significant resistance to injection. The injection site
was compressed for a few moments for the purposes of haemostasis before returning
the animal to its cage. The technique for tail vein injection is shown in Figure 12.
The AdenoCre used in these experiments was an El-deleted, replication-deficient,
serotype 5 adenovirus expressing Cre recombinase under control of the CMV
promoter. An "empty" adenovirus of the same serotype without transgene was used
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a.The mouse is restrained in a specially designed commercial restaining device. b.The 29G needle is introduced into the lateral tail vein,
c. If the needle is correctly sited in the vein, the skin of the tail will blanch upon injection,without subcutaneous swelling.








































































Quantification of Preneoplastic Foci
Individual preneoplastic foci were identified and marked on H&E stained liver
sections by a fiver pathologist blinded to the experimental protocol. The area of each
fiver section was determined by capturing a digital image of the section using a low-
powered microscope (x 2.5 magnifcation) with the section adjacent to a scale bar.
The area of the section was then determined using Image-ProPlus image analysis
software (Media Cybernetics, Silver Spring, Maryland), and the area of individual
foci determined using PALM RoboSoftware (Zeiss).
Quantification of Apoptosis
Apoptotic cells were identified on H&E stained fiver sections the basis of
morphological criteria (cell shrinkage, chromatin condensation, margination, and
apoptotic bodies). Results are expressed as the number of apoptotic bodies in 50
random high-powered fields (hpf).
Quantification of Necrosis
Necrosis was estimated on the basis of differential staining between necrotic tissue
which stains predominantly pink and non necrotic tissue which with H&E staining
appears blue. Using a macro designed within an image software analysis program
(KS 400, Carl Zeiss Microimaging, www.zeiss.de) the proportion of necrotic and
non necrotic tissue in each view can be estimated. Four low-powered images (x5
magnification) were captured for each tissue section. Vascular structures were
excluded from analysis using Adobe Photoshop (Seattle, Washington). The
percentage area of each section occupied by necrotic tissue was estimated and
averaged for the four sections.
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Quantification of PCNA staining in preneoplastic foci.
The percentage of hepatocytes positively stained for PCNA within a total of 62
preneoplastic foci within 11 sections from AdCre treated male mice from the
carcinogenesis protocol, was estimated using parallel H&E stained sections to help
identify foci. The percentage of PCNA-positive hepatocytes within these foci was
compared with the percentage ofpositive hepatocytes in a minimum of 500
hepatocytes outwith the preneoplastic tissue, or "non lesional" liver.
Laser Capture
Preneoplastic foci were dissected from paraffin fixed liver sections. To aid the
identification of foci in liver sections, two adjacent sections were taken from each
paraffin block of tissue - an 8 pm section and a 4 pm section. Laser capture of
preneoplastic foci was performed on the 8 pm liver sections on a plain glass slide
stained in H&E (without mounting medium or cover slips) using the P.A.L.M.
Combi System (P.A.L.M. Microlaser Technologies, Germany). The adjacent 4pm
section was stained in H&E, and mounted for light microscopy to aid identification
of foci.
Extraction and purification ofgenomic DNA
DNA was extracted from murine liver using the Qiagen DNeasy ® Tissue Kit.
(Qiagen). The principle of the system was the selective binding ofDNA to a silica
gel membrane following a proteinase K digest. The selectively bound DNA was
retained on the membrane following centrifugation. Following two washing steps the
DNA was eluted using a Tris based elution buffer.
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PCR reactions
Polymerase Chain Reactions (PCR) were carried out on Thermo Fast® 96 Skirted
Low Profile PCR plates (Abgene ) and sealed using a Thermo-Mat™96 (Abgene cat
no AB-0427).
.PCR reactions were performed using an EppendorfMastercycler. PCR products
were diluted 5:1 with Invitrogen PCR loading dye and 10 pi of this mixture was run
per well on a 1.5% agarose gel. All PCR reagents were obtained from Invitrogen.
PCR Primers















dH20 17.25 pi 24.75 pi
10x PCR Buffer 5 pi 5 pi
W1 detergent 2.5 pi 0
DMSO 2.5 pi 0
Mg (50 mM) 2 pi 1.75 pi
dNTP (1.25 mM) 8 pi 8 pi
Primer (10 pM) 2.5 pi each 2.5 pi
Taq Polymerase 0.25 pi 0.5 pi




Melting 94°C 5 mins 94°C 5 mins
Melting 94°C 1 min 94°C 30sec
Annealing 62°C 1 min 58°C 30sec
Extension 72°C 1 min 72°C 50sec
Cycles 35 35
Statistical Analysis
Graphs were prepared, and statistical analyses performed using GraphPad Prism ©





Rb floxed alleles can be deleted in the mouse liver using a Cre Lox
system of conditional gene targeting.
Conditional gene targeting allows temporal and organ-specific control over gene
deletion. One method of conditional gene targeting is CreLox technology. The mice
used in these experiments have LoxP sequences flanking exon 19 in both Rb alleles
(Vooijs et al. 1998). This arrangement is described as the allele being "floxed". The
enzyme, Cre recombinase, catalyses a recombination between the two LoxP sites,
resulting in excision of the interposing DNA. The resulting frameshift produces a
truncated non functional Rb protein. The mutation resulting from Cre-mediated
recombination is similar to that engineered through conventional means and is
therefore equivalent to a null allele. (Clarke et al. 1992)
A requisite step in ensuring recombination of floxed sequences is the effective
delivery of the Cre recombinase enzyme to the floxed sequence. Tissue-specific
expression can be achieved using Cre expression driven by a tissue-specific promoter
(Huelsken et al. 2001;Vooijs et al. 2002;Wagner et al. 1997) which may, or may not,
be combined with a ligand based expression system giving temporal control
(Tannour-Louet et al. 2002). An alternative is the use of an adenoviral delivery
system. Human adenoviruses of serotype 2 and 5 are popular candidates in the
development of gene therapy techniques. Such vectors are relatively stable in vitro,
can be produced at high titres, and do not integrate their genomes into host cells.
These characteristics make such viral delivery systems relatively safe (reviewed
(Barnett et al. 2002). An additional advantage is that adenoviruses do not require host
cells to be replicating for expression of the viral transgene. One of the biggest
potential drawbacks of the use of these vectors in human gene therapy is their limited
uptake by a number ofepithelial tissues, limiting their usefulness in, for example, the
targeted treatment of lung epithelium (Crystal et al. 1994). This tissue specificity is
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due to the selective expression of the Cocksackie Adeno Receptor (CAR), the
primary method of cellular uptake of these viruses in both humans and mice
(Bergelson et al. 1997;Tomko et al. 1997). When designing these experiments it was
possible to take advantage of the fact that the CAR receptor is preferentially
expressed in the liver;when the adenovirus is given intravenously, more than 90% of
the dose is delivered to the liver (Herz et al. 1993;Kass-Eisler et al. 1994).
In these experiments, intravenous delivery proved essential to achieving
recombination; even when relatively large doses (up to lxlO10 plaque forming units
(pfu)) of AdenoCre virus was administered via intra peritoneal injection there was no
deletion in the liver. This is fitting with observations that efforts to use an adenoviral
vector to deliver transgenes in order to treat malignant peritoneal disease produce
variable expressions in the abdominal viscera (Saimura et al. 2002). However, when
the AdenoCre virus was administered via tail vein injection, the levels of
recombination achieved were proportional to the viral titre used. Figure 13
demonstrates in vivo recombination of floxed Rb sequences. Figure 14 demonstrates
liver-specific recombination of floxed Rb sequences. High viral titres (1010 pfu)
were found to be associated with increased mortality when combined with
regenerative procedures such as PH, or CC14 treatment, suggesting combined
toxicity of the AdenoCre virus when given with a second insult. For this reason an
AdenoCre viral titre of lxl09 pfu, which did not quite achieve complete
recombination at 24 hours but did produce levels of recombination comparable to
that achieved in vitro, was chosen for the remainder of the in vivo experiments.
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Figure 13. PCR detection of recombined Rb floxed alleles. Lanes 1-9 represent
genomic DNA taken from the livers of mice 24 hours following injection with
AdenoCre. Lanes 1-3 = dose of 1x10s p.f.u. Laness 4-6 = dose of 1x109 p.f.u. Lanes 7-9
= dose of 1x101° p.f.u.. n=3 for each viral dose. Lane 10 is liver DNA from an untreated
mouse (negative control). Lane 11 is DNA from hepatocytes treated in vitro (positive
control). Lane 13 is molecular markers. 1.5% agarose/ethidium bromide gel.
Figure 14. PCR detection of recombined Rb floxed alleles in various tissuses as
indicated. Lanes 1-5 = genomic DNA samples extracted from different mouse organs
24 hours following intravenous injection of 1x10s p.f.u. AdenoCre virus. Lane 7 =
control DNA from in vitro experiments (positive control for recombination).
Recombination could only be detected in the liver. 1.5% agarose/ethidium bromide gel
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Section B
The effect ofRb loss on liver regeneration in two murine models
A central aim of this thesis was to test the hypothesis that Rb plays an integral role in
the regulation of cellular proliferation in the liver. Normal rates of cell division in the
liver are extremely low, with mitotic figures demonstrable in only 1 in 20, 000
hepatocytes (Tarao et al. 1989). Therefore, in order to examine the role of Rb in an in
vivo system where hepatocytes are regenerating, it was necessary to develop a model
of liver regeneration in the mouse. The first of these was liver hyperplasia induced by
PH; the second was liver regeneration following a single toxic insult. The purpose of
employing two different models was to allow the role of Rb to be determined in two
differing environments. PH allows a simple method of inducing regeneration; the
single factor believed to drive regeneration in this model is hepatic insufficiency.
However, in terms of relevance to a clinical, or disease setting, PH has only limited
application - the analogous situation in humans being liver resection. Thus, a second
model was developed, in which liver regeneration occurs following acute cytotoxic
injury, induced by carbon tetrachloride (CC14) treatment. CC14 induces acute liver
necrosis and therefore, produces an altered environment in which liver regeneration
takes place. This altered environment is characterised by an acute inflammatory
infiltrate and hepatocyte cell death by necrosis. This type of injury, therefore, more
accurately reflects the pattern of liver damage seen in human disease.
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Partial Hepatectomy can be used to model liver regeneration in the mouse.
It was necessary to establish the model of PH prior to using this technique to
determine the contribution ofRb to liver regeneration. These preliminary
experiments were carried out using Rb floxed mice, which have a normal phenotype.
Figure 15 demonstrates the regenerative response that follows PH. During the first 30
hours post surgery, rates of hepatocyte proliferation remain very low. After 30 hours,
a rapid and synchronous entry into S phase occurs, with almost 50% of hepatocytes
staining positively for BrdU by 36 hours post surgery. There is a subsequent second
peak of regenerative activity at 72 hours. This biphasic response is similar to that
described elsewhere (Fausto et al. 1994).
CH 1 1 1 1 1
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Figure 15. Liver regeneration occurring in Rb floxed mice following PH in the absence
of adenoviral treatment. A pulse of BrdU was given 2 hours prior to culling. The
percentage of BrdU positive hepatocytes is expressed against time post PH as mean ±
SEM. (n=3-5 mice per observation)
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Carbon Tetrachloride can be used to model liver regeneration in the mouse
Again, it was necessary to establish the model of acute toxic injury using CC14
treatment prior to determining the contribution of Rb to liver regeneration in this
model. Figure 16 demonstrates the regenerative response that follows a single dose
of CC14 in Rb floxed mice. When compared with PH, S phase entry is less
synchronous, the peak of BrdU incorporation is much reduced and the period of
regeneration appears extended. These differences may reflect the fact that liver
damage, and so the drive for proliferation, evolves over a period of hours to days.
Therefore, the signal for regeneration is less discrete, resulting in a slower and less
synchronous regenerative response. Additionally, the acute inflammatory response
that accompanies regeneration following CC14 treatment may have an effect on
hepatocyte replication.
Time (Hours)
Figure 16. Liver regeneration occurring in Rb floxed mice following a single dose of
CCI4 in the absence of adenoviral treatment. A pulse of BrdU was given 2 hours prior
to culling. The percentage of BrdU positive hepatocytes is expressed against time
post PH as mean ± SEM. (3-6 mice per observation)
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AdenoCre has no effect on the levels of liver necrosis following carbon
tetrachloride.
To ensure that the recombination event had no effect on the amount of necrosis
produced by the single dose of CC14, the percentage area of necrosis was estimated
and compared between mice with, and without, adenoviral treatment prior to
administration of CC14 (Figure 17).
Figure 17 Percentage of necrosis 24 hours following a single dose of carbon
tetrachloride in mice previously treated with AdCre (n=6) or no virus (n=4). Results are
expressed as the average of each group+/-SEM.
Rb loss can be used in conjunction with models of regeneration to determine the
effect of Rb loss on the regulation of hepatocyte replication.
To determine how acute Rb loss affects the process of regeneration, rates of liver
regeneration were examined in the two different models following acute Rb loss.
AdenoCre virus was used to produce recombination in the Rb flox/flox mice. BrdU
incorporation during the regenerative response was then examined. The experimental
protocol is shown in Figure 18. BrDU was given 2 hours prior to terminal
anaesthesia.
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Figure 18. Experimental Protocol to determine the role of Rb in liver regeneration.
BrOU
IV AdCre PH/CCI4 End Point
injection ... . .
Terminal anaesthesia at
24,36,48,60,72,96 or 120 hours
following PH/CCI4
Rb loss accelerates cell cycle entry and brings forward the peak of DNA
synthesis of liver regeneration following partial hepatectomy.
As demonstrated in Figure 19 and Figure 20, when AdenoCre was given prior to PH,
Rb deletion induced premature S phase entry compared to empty vector controls.
Average rates of BrdU incorporation were 28.4 ±6.1 % (SEM+/-6.14356%) in
AdenoCre treated mice at 24 hours post PH vs 2.7 ± 1.3 % (SEM +/-1.260539%) in
empty vector treated mice. The maximum rate of proliferation occurred at 30 hours
post PH in the Rb deleted mice (AdenoCre treated mice) and 36 hours in the empty
vector treated mice. The rate ofDNA synthesis in the AdenoCre treated group was
persistently higher for the duration of the time course compared to empty vector
treated controls. Analysis by two-way ANOVA revealed Rb loss had a significant
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Figure 19. The effect of Rb deletion on liver regeneration following PH. The two curves
represent Rb floxed mice treated with either AdenoCre or an empty adenovirus 24
hours prior to PH. A pulse of BrdU was given 2 hours prior to culling. The percentage
of BrdU positive hepatocytes is expressed against time post PH as mean ± SEM. (n=3-
5 mice per observation). Two-way ANOVA analysis of the two regenerative curves
revealed Rb deletion had a significant effect on BrdU incorporation (P<0.0001)
1
Figure 20. BrdU staining following PH in mice treated with AdenoCre (A) or empty
vector control virus (B). Darkly stained nuclei are BrdU positive. Bar Scale represents
50 pm.
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Rb loss accelerates cell cycle entry and brings forward the peak of DNA
synthesis during liver regeneration following acute liver necrosis.
The effect of Rb loss in liver regeneration following CC14 treatment was similar to
that following PH (Figure 21 and Figure 22). When AdenoCre virus was
administered 24 hours prior to CC14 treatment, Rb deletion produced premature entry
into S phase as assessed by BrdU incorporation. Rates ofBrdU incorporation at 36
hours were 66.1 ± 3.9 % (SEM+/-3.9) in AdenoCre treated mice compared to 9.1 ±
4.4 % (SEM+/-4.4%) in mice treated with empty vector control virus. Maximum
rates of BrdU incorporation occurred at 36 hours following Rb deletion (AdenoCre
treatment) compared to 60 hours in the empty vector treated control group. Higher
rates ofDNA synthesis were maintained in the AdenoCre treated group compared to
the empty vector treated group throughout the duration of the experiment.
Interestingly, regeneration in the Rb deleted (AdenoCre treated) group showed a
biphasic pattern of regeneration with a peak at 30 hours, followed by a second peak
at 60 hours. This biphasic pattern contrasts with the single peak of regeneration seen
in the empty vector treated group. Analysis by ANOVA revealed Rb deletion had a
significant effect on the rate of BrdU incorporation compared with empty vector
treatment (PO.OOO 1 ;Figure 21)
100
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Figure 21. Liver regeneration in response to a single dose of CCI4. The two curves
represent Rb floxed mice treated with either AdenoCre or an empty adenovirus 24
hours prior to CCI4 treatment. A pulse of BrdU was given 2 hours prior to culling. The
percentage of BrdU positive hepatocytes is expressed against time from CCI4
injection as mean ± SEM. (n=3-5 mice per observation). Analysis of the two
regenerative curves by two-way ANOVA revealed Rb deletion had a significant effect
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Figure 22. BrdU staining following CCI4 treatment in combination with empty vector
control virus (A) or AdenoCre (B). Darkly stained nuclei are positive for BrdU. Bar
Scale represents 50 pm.
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Section C
The effect of Rb loss on liverpolyploidisation in two murine models
Polyploidisation is a process of unknown significance, which occurs in parallel with
normal liver growth. Levels ofpolyploidy normally increase during
regeneration(Sigal et al. 1999). Because polyploidisation is associated with an
increase in gene copy number, a reduced sensitivity to mitogens (Rajvanshi et al.
1998) and an increased sensitivity to apoptosis, it has been suggested that this
process may be protective against carcinogenesis. Conversely, it has been suggested
tetraploid cells may form an important intermediary in the development of
aneuploidy, which is an important event during carcinogenesis (Fujiwara et al.
2005;Margolis 2005;Storchova et al. 2004). Both p53 and pRb have been implicated
in the regulation of polyploidy through their involvement in centrosome duplication
(Borel et al. 2002b) and regulation of a putative "tetraploidy checkpoint" (Margolis
2005;Storchova et al. 2004). In order to determine how loss of Rb may affect
polyploidisation in the regeneration following both PH and acute necrosis, the
percentage of nuclei exhibiting each polyploidy class during the regenerative
response was analysed.
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There is a polyploidizing pattern of growth in the regeneration that follows both
PH and CCI4 administration.
Firstly, the normal changes in polyploidisation that occur during liver regeneration
following PH and CC14 were characterised using Rb floxed mice that had not been




























Figure 23. Changes in nuclear ploidy following PH in Rb floxed mice. The percentage











Figure 24. Changes in nuclear ploidy following a single dose of CCI4 in Rb floxed
mice. The percentage nuclei of each class is expressed against time from CCI4 as
mean ± SEM. (n=3-6 mice per observation)
Figure 23 and Figure 24 demonstrate that during regeneration in both models there is
a fall in the number of diploid cells and an increase in the number of cells of higher
polyploidy. This is particularly obvious in regard to the increase in the percentage of
8N nuclei. This polyploidising growth pattern is typical of liver regeneration(Sigal et
Rb deletion is associated with a loss of the normal process of polyploidisation
that occurs during liver regeneration in two different models
To determine the effect of Rb on the normal polyploidizing growth pattern that
occurs following both PH and CC14 treatment, the changes that occurred in ploidy
following treatment with either AdenoCre or empty vector control virus were
analysed. For ease of comparison, the ploidy classes have been amalgamated to show




Effect of Rb deletion in polyploidisation following PH
Figure 26 and Figure 25 show the effect of Rb deletion on the polyploidisation that
normally occurs following PH. Interestingly, loss of Rb was associated with an
increase in the percentage of diploid nuclei, with a corresponding fall in the
percentage ofpolyploid nuclei whose DNA content was 4N and greater. 96 hours
post PH there was a significantly higher percentage of diploid nuclei in Rb deleted
(AdenoCre treated) mice compared to empty vector treated control mice (43.6 ±
4.7%; vs 26.1 ± 1.0 %; n=5 for both treatments; P=0.006; student's t test) The very
large nuclei typically seen during regeneration following empty vector treatment
(Figure 27) were not seen following AdenoCre treatment.
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Figure 25. The effect of Rb deletion on the percentage of diploid cells following PH in
Rb floxed mice. The percentage diploid nuclei is expressed against time post PH as
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Figure 26. The effect of Rb deletion on the percentage of polyploid nuclei (4N and
greater) following PH in Rb floxed mice. The percentage of polyploid nuclei is
expressed against time post PH as mean ± +/-SEM. (n=3-6 mice per observation)
Figure 27. Typical large polyploid nuclei seen 120 hours following CCI4 treatment.
Scale Bar represents 50 pm.
106
Effect of Rb deletion on polyploidisation following acute necrosis
Rb deletion had a similar effect on polyploidisation following CC14 treatment as PH
as shown in Figure 28. Again, there was not the same fall in the percentage of diploid
nuclei, nor the same rise in the percentage of polyploid nuclei following Rb deletion
(AdenoCre treated) compared to empty vector treated controls. 120 hours post CC14
treatment, the percentage of diploid nuclei in the AdenoCre treated group tended be
to greater than that in the empty vector treated control group (49.4 ± 3.9 % vs 37.0 ±
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Figure 28. The effect of Rb deletion on the percentage of diploid nuclei following CCI4
treatment in Rb floxed mice. The percentage of diploid nuclei is expressed against
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Figure 29. The effect of Rb deletion on the percentage of polyploid nuclei (4N and
greater) following CCI4 treatment in Rb floxed mice. The percentage of polyploid
nuclei is expressed against time post PH as mean ± SEM. (n=3-6 mice per
observation)
These results suggest Rb deletion is associated with a reduction in the normal
polyploidising growth pattern seen after both PH and acute necrosis. As already
demonstrated, loss of Rb is associated with increased proliferative rates in both the
PH and CC14 models of liver regeneration. Increased proliferation might have been
expected to increase polyploidisation, but surprisingly, the reverse was demonstrated.
This is an unexpected and interesting result.
108
Section D
The effect of Rb loss in a Model of Carcinogenesis
After demonstrating that Rb deletion de-regulated the processes of liver regeneration
and polyploidisation following both PH and acute necrosis, the longer term effects of
Rb loss in an environment of sustained inflammation and DNA damage (as is the
case in chronic liver disease in humans), were investigated. During the prolonged
period of chronic inflammation that precedes the development ofHCC in humans, a
strongly pro-proliferative environment exists. Such an environment produces a
selection pressure for those hepatocytes that have acquired advantageous mutations
during this period (Thorgeirsson et al. 2002a). In an attempt to reproduce these
elements of a mutagenic and pro-proliferative environment, diethylnitrosamine
(DEN) treatment, a well-characterised mutagenic compound that produces DNA
adducts, was combined with repeated administration of CC14. The protocol for these
experiments is summarised in Figure 30. These experiments were designed to test the
hypothesis that loss of Rb can provide hepatocytes with a selective advantage in this
environment. The protocol was necessarily short because the aim was to
subsequently compare the additive effect of p53 deletion in combination with Rb
loss. p53 deletion results in mice with a shortened life span (Donehower et al.







Figure 30 The carcinogenesis protocol for investigating the longer term effects of Rb
deletion. DEN was given as a single intraperitoneal injection at 14 days of age and
AdenoCre was administered via tail vein injection at 6 weeks of age. CCI4 was
repeatedly administered weekly as an intraperitoneal injection over the following six
weeks.
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Rb has no effect on survival in a model of carcinogenesis
If loss of Rb is an important factor in the development ofHCC, it might have been
expected that Rb deletion would have an effect on mortality rates following 12 weeks
of this carcinogenesis protocol. Although mortality rates tended to be higher in the
AdenoCre treated group compared to the vector treated control group, this trend did
not reach significance at 12 weeks, as shown in Figure 31. It is possible that a longer
protocol may have increased the difference in survival between these two groups.
The mortality in both of these groups is more likely to reflect the acute toxicity of the
protocol, rather than a result of the histological changes occurring in the liver,
because, as discussed later in this section, such lesions develop at an early stage and
represent a small fraction of the total liver area.
Week
Figure 31 Survival curves comparing the effect of AdenoCre treatment vs empty
vector control treatment in a carcinogenesis model of 12 weeks duration. There was
no significant difference between the two curves (Log Rank test;P>0.05 p=0.3449)
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Figure 32.Comparison of the effect of sex on the development of preneoplastic foci.
The number of foci per unit area tissue is expressed for male (n=12) and female (n=8)
following AdenoCre treatment in the carcinogenesis protocol. (p<0.001 in unpaired t
test).
Male sex is associated with an increased risk for the development ofHCC in both
mice and humans(Bosch et al. 1999a). It has been argued that such an increased risk
in men is secondary to lifestyle factors, such as a higher alcohol intake (Lai et al.
1987). However, these data are more fitting with previous findings showing male sex
is a strong independent risk factor for the development ofHCC in mice (Ghebranious
et al. 1998)
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Rb loss functions to accelerate the rate of preneoplastic change in a model of
carcinogenesis
There were a number of prominent histological features demonstrable in the liver
following the carcinogenesis protocol. These included:
• The appearance ofmultiple preneoplastic foci
• High levels of hepatocyte apoptosis
• Occasional foci of dysplastic hepatocytes
The predominant histological feature was the development ofmultiple preneoplastic
foci, typical examples of which are shown in Figure 33. These foci were made up of
small, round cells and displayed either a basophilic or a clear cell phenotype.
Figure 33. H&E stained liver sections showing typical preneoplastic foci comprised of
non-encapsulated clusters of small basophilic staining hepatocytes.
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Preneoplastic Foci stain positively for markers of cell proliferation
Preneoplastic foci are believed to represent the clonal expansion of hepatocytes that
harbour mutations advantageous to tumour development. One characteristic of these
foci is increased cell replication compared to hepatocytes out with the foci (Schulte-
Hermann et al. 1993). To determine whether the foci seen following this
carcinogenesis protocol represented hyperplastic cell populations,
immunohistochemistry to detect the proliferation markers, Ki67 and PCNA, was
performed (Figure 34). Positive staining for these markers was demonstrable within
preneoplastic foci, but was rarely seen in the surrounding tissue. Quantification of
the percentage of positive cells present in the foci of AdenoCre treated mice
compared to areas of surrounding tissue demonstrated a significantly higher rate of
hepatocyte division in these abnormal preneoplastic foci. (Figure 35)
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Figure 34. Immunohistochemistry of a typical preneoplastic focus showing positive




















Figure 35. The total percentage of hepatocytes positively stained for PCNA and Ki67
within preneoplastic foci compared to normal tissue. The total number of foci counted
was 62 across 8 different animals. Comparison was made against the percentage of
positively staining hepatocytes from a minimum of 500 hepatocytes outwith the foci.
(P= 0.0006; paired t-test).
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Rb loss increases the frequency, size of and fractional area of preneoplastic foci
in a model of carcinogenesis
In order to quantify the preneoplastic foci that characterised the liver histology
following the carcinogenesis protocol, a method of image analysis was developed
similar to previously described methods (Pierce et al. 2002). This allowed
quantification of the size of individual foci, the number of foci per unit tissue area
and the total cross sectional area made up of preneoplastic tissue.
Quantification of the size of individual preneoplastic foci in male mice demonstrated
that Rb deletion (AdenoCre treatment) resulted in foci that were significantly larger
compared to those in the empty vector treated control animals (83300 ± 8553 pm ;
n=12 vs 29980 ± 6802 pm2; n=6; P= 0.0009, students t test. (Figure 36). The
number of foci per unit of section were also significantly increased in the AdenoCre
treated group compared to the empty vector treated control group (0.074 ± 0.011
foci/mm2; n=12 vs 0.023 ± 0.006 foci/mm2; n=6; /M1.0058; students t-test; Figure
37). This meant preneoplastic tissue occupied a greater proportion of the tissue in the
Rb deleted (AdenoCre treated) animals compared to the empty vector treated control













Figure 36. Effect of Rb deletion on the size of preneoplastic foci in male mice treated

















Figure 37. Effect of Rb deletion on the percentage area of preneoplastic tissue in male
















Figure 38. Effect of Rb deletion on the number of preneoplastic foci per unit area of
tissue section in male mice treated in the carcinogenesis protocol.
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Rb loss is associated with increased levels of apoptosis in a model of
carcinogenesis
One of the notable characteristics of the livers ofAdenoCre treated mice compared to
the livers of empty vector treated control mice in the carcinogenesis protocol was the
presence of high levels of apoptosis. Quantification of levels of apoptosis based on
morphology (typical morphology is demonstrated in Figure 40) revealed that male
AdenoCre treated mice (n=12) had significantly elevated levels of apoptosis




















Figure 39. Quantification of apoptosis in liver sections from AdenoCre treated mice
compared to empty vector treated control mice following the carcinogenesis protocol.
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Figure 40. H&E stained liver section showing a typical apoptotic body. (x40
magnification)
Rb null cells persist following a period of chronic inflammation in a model of
carcinogenesis
If Rb deletion provides a proliferative advantage to Rb null hepatocytes, then one
might reasonably predict that Rb null hepatocytes should be detectable at the end of
the carcinogenesis protocol, 6 weeks following AdenoCre treatment. PCR performed
on genomic DNA extracted from liver at the end of the protocol demonstrated
recombined DNA was present (Figure 41).
-DL70 AdCre
100% 300bp
Figure 41. PCR detection of recombined Rb floxed alleles. Lanes 1-3 represent
genomic DNA taken from the livers of mice following completion of the
carcinogenesis protocol 6 weeks post injection of the control virus (DL-70). Lanes 4-9
represent genomic DNA taken from the livers of mice following completion of the
carcinogenesis protocol 6 weeks post injection of the AdenoCre virus. Lane 10 is DNA
from hepatocytes treated in vitro with AdenoCre virus (positive control). Lane 12 is
molecular markers. 1.5% agarose/ethidium bromide gel
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Rb loss can be demonstrated in both preneoplastic foci and in non lesional
tissue in livers following the carcinogenesis protocol.
Rb deletion (AdenoCre treatment) was associated with an increase in the prevalence
of preneoplastic foci compared to that in empty vector treated control mice. To
determine whether these foci represented populations ofRb null cells, laser capture
mico-dissection was used to isolate these foci in order to compare their cellular
composition with that of surrounding tissue.(Figure 42) Rb loss could be
demonstrated in both preneoplastic foci and surrounding non lesional tissue.
However, it was not possible to demonstrate a non-recombined allele in neither
preneoplastic foci nor the surrounding non lesional tissue. Indeed the non
recombined allele could not be demonstrated in untreated laser dissected control
tissue, presumably because the process of laser dissection produces DNA fragments
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Figure 42. PCR detection of recombination in Rb floxed alleles in ONA extracted from
laser-dissected areas of normal liver tissue (N), or areas of preneoplastic foci (F)
following DEN-induced carcinogenesis and AdCre treatment. Lanes 1-6 = DNA
extracted from normal tissue or foci as indicated. Bar represents dissections made
from one individual slide. Lane 7 = genomic DNA from hepatocytes treated with
AdCre in vitro (positive control). Lane 8 = DNA extracted from hepatocyes treated in
vitro with empty adenovirus (negative control). Lane 9 = molecular markers
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In mice homozygous for p53 Rb loss may accelerate dysplastic change in a
model of carcinogenesis
It has been widely demonstrated that Rb loss is associated with p53 stabilisation and
increased levels of apoptosis (Macleod, Hu, & Jacks 1996;Pan, Yin, Dyson, Harlow,
Yamasaki, & Van Dyke 1998;Tsai, MacPherson, Rubinson, Crowley, & Jacks 2002).
It has been suggested loss of p53 might, therefore, be essential for neoplastic
transformation of Rb null cells (Williams et al. 1994a). To determine the effect of
p53 loss in combination with Rb deletion, the carcinogenesis protocol was repeated
using Rb floxed mice crossed with p53 null mice (Figure 43). Histological
examination of these livers by an experienced liver pathologist demonstrated that
compared with Rb loss alone, mice deficient in both p53 and Rb exhibited an
additional, and striking diffuse increase in hepatocyte turnover, manifesting as
increased mitosis and cell death - both apoptosis and single cell necrosis with
inflammation (spotty necrosis). The cytological appearance of hepatocytes was even
more extremely deranged than in the Rb-deficient animals. The changes were
notably distributed throughout the liver, rather than clustered in the relatively
atypical foci seen following Rb deletion alone. These changes could be attributed, to
some degree, to synergistic effects between p53 deficiency and viral treatment.
Because a further control of p53 null mice treated with empty adenovirus was not
employed it is not possible to completely exclude this possibility. However, this
seems an unlikely explanation for the gross effects seen here for two reasons; firstly,
empty adenoviral treatment appeared to have only a minimal effect when given to Rb
floxed p53 wild type mice and secondly, it has been demonstrated that p53 is
required for adenovirus of this type to have a cytopathic effect (Hall et al. 1998).
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Figure 43 Altered histology of double Rb/p53-deficient livers after DEN/CCI4 injury.
Loss of Rb on a p53-deleted background (A & B) was characterised by diffuse
changes of increased hepatocyte size, extreme nuclear pleomorphism (arrow 1),
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abnormal mitoses (arrows 2&4) and spotty hepatocyte necrosis (arrows 3&5). These
changes were distinct from the phenotype produced by Rb deletion alone, where
background hepatocyte nuclear enlargement and pleomorphism was present but
comparatively markedly reduced (similar to p53-null hepatocytes), and features of
markedly increased turnover (apoptosis, mitoses) and mitotic instability were absent




Rb loss deregulates the processes of liver regeneration in two different
models
To determine the role of Rb in the regulation of liver regeneration, two models of
liver injury were developed, which, when combined with AdenoCre treatment,
allowed the consequences ofRb loss on hepatocyte proliferation to be examined in
vivo.
Both partial hepatectomy and acute necrosis following AdenoCre treatment resulted
in accelerated entry into S phase of the cell cycle. Higher rates ofDNA synthesis
were maintained throughout the time course, with the peak ofDNA synthesis
occurring earlier than in controls. These observations suggest Rb negatively regulates
cell cycle progression during liver regeneration. These findings are in keeping with
the accepted role of pRb as a regulator of both the restriction point, and the G2/M
checkpoint. Loss of Rb has a similar effect on proliferation in many different
experimental systems, including, importantly, isolated primary hepatocytes in
v/7ro(Sheahan et al. 2004a). However, this is the first report of such a role for Rb
being demonstrated in the regulation of liver regeneration in vivo.
The levels of pRb were not determined in these experiments, though previous work
has demonstrated levels of pRb are normally extremely low in the quiescent
liver(Garriga et al. 1998) and increase dramatically during liver regeneration (Fan et
al. 1995). Both hypo- and hyper- phosphorylated forms of pRb are found in the time
course following PH, with levels of phosphorylation increasing rapidly during Gl.
The phosphorylation status of pRb controls its activity such that
hyperphosphorylation induces conformational change in the pocket region of the
protein, reducing its binding affinity for E2F and, therefore, permitting cell cycle
progression. It is interesting that hypophosphorylated forms of pRb persist
throughout liver regeneration, which suggests the rate of progression through the
restriction point may be controlled by both the absolute levels of pRb, and also the
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ratio of phosphorylated to hypophosphorylated forms, i.e. the balance between active
and inactive forms. Such a hypothesis would fit with the observations presented in
this thesis, for; if pRb was entirely hyperphosphorylated (deactivated) from the
outset of, and throughout regeneration, then the somatic loss of Rb engineered here
might have been expected to have had no additional effect. However, in these
experiments, loss of Rb resulted in a reduction in the time between stimulus and S
phase entry, indicating a shorter G1 phase of the cell cycle. In addition, the normally
biphasic cell cycle entry typical of liver regeneration, was disrupted and increased
rates ofDNA synthesis occurred throughout the time course. Thus, it would appear
Rb has an important function in regulating both rate of entry into the cell cycle and
the co-ordination of hepatocyte replication.
Although no previous attempts have been made to determine the role of Rb in the
regulation of liver proliferation, the role of composite members of the Rb pathway
has been examined. Loss of inhibitors ofRb, including the cyclin kinase inhibitor,
p21, deregulates liver regeneration in a similar manner as loss of Rb - a shortened
G1 phase , associated with Rb hyperphosphorylation (Albrecht et al. 1998b;Jaime et
al. 2002). Alternatively, loss ofpi 8, belonging to the second family of cyclin kinase
inhibitors, the INK4 family, has little effect on liver regeneration in isolation, but co¬
operates with p21 and p27 to regulate both the length ofGl, and the maximum rate
ofDNA synthesis (Luedde et al. 2003). The role of activators of Rb has been
examined using an adenoviral delivery system to increase cyclin D expression in the
murine liver. This resulted in DNA synthesis, mitosis, and increased liver weight.
However, the effects were only short lived, and the role of increased cyclin D
expression on liver regeneration was not examined (Nelsen et al. 2001b). The
phenotype of deregulated proliferation that results from Rb loss is believed to be a
consquence, at least in part, of increased E2F activity. Liver specific over-expression
of E2F-1 in a murine model increased the basal rate of hepatocyte proliferation, but
surprisingly had little effect on hepatocyte proliferation following PH (Conner et al.
2000). This may be because Rb is known to exert a negative influence on cell cycle
progression through a number of different mechanisms in addition to that of
sequestering E2F family members, including directly inhibiting the transcription
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machinery, such that in the regulation of liver regeneration loss of E2F1 may not
equate with that ofRb loss. It is interesting that both loss ofRb inhibitors, and
increased levels of Rb activators, have an effect on hepatocyte proliferation in vivo.
Such an observation provides support for both the theory (Vogelstein et al. 2004) and
in vivo evidence (Edamoto et al. 2003) that there operates within the development of
HCC an "exclusivity principle" which suggests the loss of only one of the negative
regulators, or increased activity of one of the activators, of the pathway is required to
produce the same functional outcome.
The results presented in this thesis demonstrate an important role for Rb in the
regulation of hepatocyte turnover, specifically during those conditions when
hepatocytes are driven to proliferate. Such findings suggest loss ofRb function could
be a significant event in the development ofHCC. The environment of chronic
inflammation which precedes the development ofHCC is characterised by continual
regeneration, during which hepatocytes are constantly driven to proliferate by a
number of factors including ongoing hepatocyte necrosis and death, as well as
increased expression of liver mitogens including TGFa and HGF (Grisham 2001a).
The rate of hepatocyte proliferation correlates directly with the frequency of tumour
development in the liver (Borzio et al. 1998). Loss of heterozygosity of Rb has been
demonstrated in cirrhosis accompanying HCC (Ashida et al. 1997), which suggests
that loss of regulation of regeneration by pRb may occur early in the development of
HCC. Loss of Rb function in such an environment would provide a clear
proliferative advantage allowing for clonal expansion of hepatocytes lacking
functional pRb.
The most common aetiological factor in the development of HCC is infection with
the hepadnavirusus. Both Hepatitis B and Hepatitis C infection drive hepatocyte
proliferation as a consequence of chronic inflammation. Indeed, the inflammatory
response to viral infection is required for the development of HCC. (Nakamoto et al.
1998;Nakamoto et al. 2002). In addition to this non-specific effect of viral infection,
viral proteins also have specific interactions with the cell cycle machinery. (Feitelson
et al. 2005) Hepatitis C core protein appears to increase pRb phosphorylation and
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E2F activity in vitro (Ghosh et al. 1999;Hassan et al. 2004). HBx has similar effects
on the function of pRb, both directly and indirectly, through p21(Sirma et al. 1999b).
Therefore, hepatitis infection may be such a powerful aetiological factor in the
development of HCC because it has the ability to simultaneously drive hepatocyte
proliferation, while abrogating the ability of pRb to negatively regulate cell cycle
progression.
In addition to conferring a proliferative advantage on hepatocytes, loss of Rb may
confer a number of further advantages to incipient tumour cells. Rb has been
ascribed a role in maintaining the stability of the genome through its regulation of the
G2M checkpoint, interacting with the protein phosphatases la (Durfee et al. 1993)
and Heel (highly expressed in cancer 1), (Zheng et al. 2000) to ensure faithful
chromosomal segregation. Rb may also have a role in the regulation of centrosome
duplication (Borel et al. 2002a;Meraldi et al. 1999). In the absence ofRb, high rates
of proliferation lead to the accumulation of markers of chromosomal damage in
mouse embryonic stem cells (Zheng et al. 2002). Thus the absence of Rb may
contribute directly to defects in mitosis and genetic instability. It would be of interest
to determine whether loss of Rb had a similar effect on such markers of genomic
instability following liver regeneration.
As well as direct effects on mitosis, the absence of Rb may also prevent replicating
hepatocytes from arresting in response to DNA damage, bypassing cell cycle
checkpoints and allowing the accumulation of further mutations in Rb null cells. pRb
is essential for effective p53-mediated cell cycle arrest following UV and y radiation
induced DNA damage in mouse embryo fibroblasts and Rb null hepatocytes
(Harrington et al. 1998;Sage et al. 2000;Sheahan et al. 2004b).In the absence of Rb,
adult mouse fibroblasts continue to replicate following DNA damage induced by
chemotherapeutic agents (Bosco et al. 2004). The process of liver regeneration
appears to involve considerable genotoxic stress and oxidative injury. PH is
associated with increased levels of p21 and the accumulation ofmarkers of DNA
damage in regenerating liver (Sigal et al. 1999), suggesting the activation of the
ATM/p53/p21 damage response pathway. It would be interesting to determine in the
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regeneration model presented in this thesis, whether loss of Rb was associated not
only with an increase in deregulated proliferative activity, but also an impaired
response to the cell cycle arrest signals which appear to operate during liver
regeneration.
The mechanism through which Rb loss deregulated liver regeneration in the
experiments presented here was not examined. A substantial body of evidence
suggests deregulated cell proliferation following Rb loss is mediated through
deregulated E2F activity. Downstream targets ofE2F include those genes which
control the machinery ofDNA synthesis (DeGregori et al. 1995a), therefore it is
reasonable to assume the link between Rb loss and increased DNA synthesis
demonstrated here is secondary to increased E2F activity, though it would be of
interest to examine how the time course of E2F was altered during the regenerative
period. A further consequence ofRb loss is increased apoptosis (reviewed (Chau et
al. 2003), which is also believed to be mediated through increased E2F activity.
There are several potential pathways through which E2F may mediate apoptosis,
both p53 independent and p53 dependent. That apoptosis may result from loss ofRb
remains a puzzle because such an observation conflicts with the role of Rb as a
tumour suppressor. Whether Rb loss resulted in increased levels of hepatocyte
apoptosis in the liver was not determined in these experiments. In order to be
confident of the implications for development of HCC of acute Rb loss in the liver, it
would be interesting to determine whether the increased proliferative activity seen in
the results of this thesis was associated with increased levels of apoptosis in the liver.
The premise of this thesis was that as a negative regulator of cell cycle progression,
the role ofRb in the liver would only be apparent when hepatocytes were dividing.
Therefore, models of liver regeneration and carcinogenesis were used to test this
hypothesis. There is evidence to suggest Rb has a role not only in governing
proliferation, but also in the control of quiescence (Sage et al. 2003). A recent paper
describes the use ofvery similar techniques to those used here, in order to examine
the effect of Rb loss on the maintenance of quiescence in the liver (Mayhew et al.
2005). Mayhew et al demonstrated that acute Rb loss in quiescent liver was
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sufficient to produce hepatocyte DNA synthesis, but not mitosis, and implied acute
loss of Rb could be an initiating event in the development of HCC. However when
considered in combination with the observation that the levels of pRb are extremely
low in quiescent liver (Garriga et al. 1998), and that, in the absence of a regenerative
stimulus, acute Rb loss simply leads to cell cycle arrest (Mayhew et al. 2005), it
seems unlikely that isolated loss of Rb in the quiescent liver is likely to be a
transforming event..
Regulation ofpolyploidisation by the Retinoblastoma Gene
The experiments described here demonstrate that when regeneration occurred
following Rb loss, the process of polyploidisation which normally accompanies rapid
liver growth was altered. Although polyploid nuclei could certainly be demonstrated
during the regeneration which followed both AdCre and empty vector treatment, the
fraction of polyploid hepatocytes was decreased following Rb loss, and the fraction
ofdiploid nuclei was increased. This was an unexpected result for several reasons.
Firstly, in keeping with initial experiments and those of others (Fukasawa 2005;Nigg
2002a) the rapid replication of hepatocytes following PH is normally associated with
an increase in the fraction of polyploid nuclei. Therefore, the increased levels of
proliferation seen following Rb loss might have been expected to produce an
increase, rather than a decrease, in levels of ploidy. Secondly, if Rb contributes to the
maintenance of genomic stability (Bosco et al. 2004), and if polyploidisation can be
assumed to be a marker of chromosomal instability, then loss of Rb might have been
predicted to increase polyploidisation. In addition, the results of this thesis directly
contradict previous results of in vivo and in vitro work that examined the effect of Rb
loss on polyploidisation in the liver. In vitro, the loss of Rb is associated with an
increase in both the rate of hepatocyte proliferation and in the levels of hepatocyte
polyploidisation (Sheahan et al. 2004c). Similarly in vivo experiments have
demonstrated liver-specific Rb loss resulted in increased levels of hepatocyte
polyploidisation (Mayhew et al. 2005).
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There are a number ofpossible explanations for these results. The first is that
regeneration following loss ofRb results in the loss of the normal polyploidising
growth pattern characteristic of hepatocytes. A second explanation is that the
increased fraction of diploid nuclei represents not a change in the growth pattern of
mature adult hepatocytes, but instead the emergence of a diploid progenitor
population whose normal growth pattern is non-polyploidising, and whose
replication is exaggerated by Rb loss, such that they expand to make up a larger
fraction of the analysed nuclei.
The interpretation of these results is somewhat restricted by limitations of the
methods employed here to determine levels of ploidy. The Vindelov preparation
involves the labelling of individual nuclei following their isolation from whole cells
by a trypsin digest of multiple liver aspirates (Vindelov et al. 1983b). The DNA
content of individual nuclei is then examined by flow cytometric analysis. Therefore,
it is only possible to comment on the change of ploidy of individual nuclei, rather
than the DNA content of individual whole cells. In the adult mouse, a large
proportion of hepatocytes are binuclear (Brodsky et al. 1977), and polyploidisation
occurs through generation of a binuclear intermediate (Guidotti et al. 2003). As the
Vindelov method does not allow analysis of the DNA content of whole cells, it is not
possible to know whether the apparent increase in the fraction of diploid nuclei
represents a genuine diploid cell population, or the expansion of binuclear
hepatocytes of 2n2n ploidy. However, it is possible to say the inverse; that there is a
fall in the prevalence of nuclei whose DNA content is 4n or greater.
The significance of polyploidy is not yet fully known, nor are the mechanisms that
govern this process. A popular, and long standing, theory in cancer biology is that
polyploidisation, particularly the formation of tetraploid cells, may represent an
intermediate step in the development of aneuploidy and cancer. This theory was
initially proposed almost 100 years ago (Boveri T 1914), and is the foundation for
the proposed "tetraploidy checkpoint", a putative, possibly p53-controlled
checkpoint, that directs cells which undergo cleavage failure into cell cycle arrest.
The theory is that if this checkpoint fails, tetraploid intermediates that possess an
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abnormal number of centrosomes are more likely to undergo an abnormal mitosis
resulting in aneuploidy (Doxsey 2001;Fukasawa 2005;Nigg 2002b;Pihan et al. 1998).
Abnormal centrosome number has been observed in a number of different human
tumours (Lingle et al. 1998;Pihan et al. 1998), and in vitro experiments have
demonstrated abnormal centrosome segregation and aneuploidy following artificially
induced cell cycle arrest (Borel et al. 2002c;Meraldi et al. 2002). Rb has been
attributed a role in the control of centrosome duplication and in maintaining cell
cycle arrest as part of the tetraploidy checkpoint (Margolis et al. 2003). It is an
attractive hypothesis that loss of Rb could lead directly to both aneuploidy and
deregulated cell cycle regulation. However, actual in vivo evidence for an obligatory
tetraploid intermediate in the development of cancer is limited to one tumour type
(Galipeau et al. 1996).
The ubiquity ofpolyploidisation in the liver seems to provide direct evidence
contrary to the theory that tetraploid cells are obligatory cancer intermediates.
Polyploidisation in the liver appears to represent a normal physiological growth
pattern. In healthy liver, ploidy increases gradually throughout development to the
point where hepatocytes of4n or greater represent the majority of hepatocytes in the
liver (Brodsky et al. 1977), and unless the normal regulatory processes of liver
growth are perturbed through chronic inflammation, liver cancer is unusual (Grando-
Lemaire et al. 1999). This suggests that in the liver, polyploidisation represents a
specialised growth strategy which presumably serves some advantage. Polyploidy
occurs unusually out with the liver (Vliegen et al. 1995) suggesting hepatocytes show
a specialised upregulation of polyploidising pathways.
An alternative theory is that polyploidisation in the liver may serve as a biological
defence mechanism, directing hepatocytes that have acquired DNA damage towards
senescence rather than apoptosis, as an economical alternative to maintain the
homeostatic function of the liver. The presence ofpolyploidy in the liver would then
be indicative of the on going replenishment of hepatocytes in a toxic environment,
rather than representing pathological intermediates in the development of cancer.
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There are a number of lines of evidence which support this theory and can explain
the presence of polyploid hepatocytes in both healthy and diseased liver. If
polyploidisation occurs in the liver as a response to DNA damage, and DNA damage
is an inevitability of cell replication, then rates of polyploidy might be expected to
increase in parallel with growth. Basal rates of hepatocyte renewal are slow, but are
associated with steady increases in levels of polyploidisation throughout the life of
the adult (Kudryavtsev et al. 1993). During periods of rapid growth, as occurs during
post natal development and regeneration, the rate ofpolyploidisation is increased in
parallel with rates of replication and presumed acquired DNA damage. A rapid
increase in polyploidisation with a concomitant increase in markers ofDNA damage
occurs following PH (Gorla et al. 2001a). Manipulation of the basal rates of
hepatocyte replication would be expected to increase polyploidisation, and this is
evident in transgenic mice that over-express mitogens (Shiota et al. 1994;Webber et
al. 1994), and in mice which are treated with exogenous thyroid hormone (Torres et
al. 1999).
Polyploidisation would also be expected to increase in conditions where the rate of
acquired DNA damage is increased, or where defects in DNA repair pathways occur.
Polyploidisation increases on weaning(Brodsky et al. 1977), presumably due to an
increase in the xenobiotic load, and following drug and toxin exposure (Bohm et al.
1981;Kato et al. 1996;Madra et al. 1995;Vindelov et al. 1983b). Increased levels of
polyploidisation have also been recapitulated in vitro in response to oxidative injury
(Gorla et al. 2001a). Conversely, polyploidisation is reduced following PH in
transgenic mice expressing antioxidants (Nakatani 1997). Loss of the DNA repair
gene, ERCC (excision repair cross-complementing rodent repair deficiency,
complementation group 1), results in gross pleomorphism and polyploidisation in the
murine liver (Chipchase et al. 2003;Nunez et al. 2000).
Hepatocytes of higher ploidy express markers of cell senescence and are less
sensitive to mitogenic stimulation (Brodsky et al. 1977;Mossin et al. 1994). It has
been suggested that transplanted hepatocytes of higher ploidy are less able to
regenerate diseased liver than those of lower ploidy (Sigal et al. 1999), though this
133
has been disputed (Weglarz et al. 2000). Together these findings make polyploid
hepatocytes unlikely progenitors in the development of carcinogenesis. Those
hepatocytes of high ploidy which have been demonstrated in CAH (Toyoda et al.
2005), cirrhosis, and in the liver adjacent to HCCs, may simply be indicative of a
preventative strategy designed to limit the consequences of increased hepatocyte
turnover in an environment of continuous DNA damage. It may be then, that loss of
polyploidisation is an important step in the development of HCC, in the same way
that loss of apoptosis or deregulated proliferation are considered obligatory steps in
the development of cancer (Hanahan et al. 2000). Loss of polyploidisation in the
liver would lead to the emergence of diploid hepatocytes that are more sensitive to
mitogenic signals and carry markers ofDNA damage, which could represent
advantageous mutations.
It is not obvious why, when regeneration occurs in the absence of Rb, as
demonstrated in these experiments, there is a loss of polyploidisation, whereas
previous work has demonstrated an increase in polyploidisation following Rb loss,
both in vitro and in vivo. As already discussed, the increased proliferation seen
following AdCre treatment might have been expected to increase rates of
polyploidisation. The purported increase in genomic instability associated with Rb
loss, may have been expected to have a similar effect, if indeed the mechanism of
polyploidisation is protective. Rb is not required for polyploidisation, as
polploidisation still occurs, albeit to a lesser degree in these experiments, so the
effect seen here is likely to be an indirect effect of Rb loss, acting in concert with
other factors through, as yet undetermined, pathways. The unique factor which may
explain the difference between these results and previous work may be the presence
of a powerful regenerative drive for hepatocyte proliferation that was not present in
previous experiments. The protective process of polyploidisation may, therefore, be
over ridden when a combination of factors, such as PH, and loss of tumour
suppression function, are combined.
Supportive of the idea of the importance of the regenerative drive in combination
with Rb loss in deregulating polyploidisation, is the observation that the fall in the
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fraction of polyploid nuclei that occurred following PH in this study was greater than
that following CC14 treatment. This may be because regeneration is less synchronous
following CCL4 treatment, and so the difference between groups at a particular time
point is less obvious. It may also be because CCL4 treatment is considered to provide
less of a regenerative drive than PH.
The effect of Rb loss in a pro-proliferative environment on the amelioration of the
process of polyploidisation and the emergence of a diploid population is in keeping
with a role for Rb in the development HCC as discussed in the first section. Loss of
Rb in the environment of chronic inflammation may select for the development of
diploid rather than polyploid hepatocytes. The pattern of HCC is characterized by the
emergence of such diploid populations (Oriyama et al. 1998;Saeter et al.
1988a;Schwarze et al. 1984c), which have also been demonstrated in preneoplastic
lesions (Saeter et al. 1988b). Similarly, transplantation of DEN-treated hepatocytes
results in the development of diploid tumours in recipient mice (Saeter et al. 1989). It
would be of interest to characterise the diploid cells that appear to dominate
following Rb loss in the experiments presented here, and, in particular, to examine
their neoplastic potential.
The pathways through which Rb loss may affect polyploidisation were not explored
in these experiments. The effects of acute Rb loss are usually attributed to increased
E2F activity (reviewed Mulligan & Jacks 1998). Although liver specific over-
expression of E2F-1 does not have a significant effect on hepatocyte proliferation
following hepatectomy (Conner et al. 2000), conditional expression of E2F-1 at
supraphysiological levels is associated with a loss of polyploidisation in vivo(Conner
et al. 2003). It may be that, in addition to their role in maintaining normal liver
physiology, the absolute levels ofE2F expression are important in determining the
fate of hepatocytes in terms of polyploidisation. It is possible that there is a threshold
of activity below which the process of polyploidisation is triggered, and above which
polyploidisation fails. The level of such a threshold may then be modulated by the
environment. Certainly the theory of a "threshold" limit for the proliferative effects
of Rb loss in the mediation of apoptosis is well described (Trimarchi et al. 2002).
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A second explanation for the increased fraction of diploid nuclei seen following Rb
loss in a model of regeneration, is the that these nuclei may actually represent the
expansion of a diploid cell population on which Rb loss has a greater effect than
native hepatocytes. The preferential expansion of a trans-differentiated progenitor
population is one possibility.
Although the existence of a progenitor population, derived from intra and extra
hepatic "stem cells" has been described previously in the liver (Evarts et al.
1987;Sell 1990a), the extent to which such a population contributes to regeneration is
a contentious issue, and an uneasy consensus exists at present that acknowledges the
presence of such a population, but apportions it a limited contribution to regeneration
in the normal liver (Fausto 2004a). The prevalence of this population is greatly
increased in certain experimental systems where the replication of adult hepatocytes
is inhibited (Sell 2001;Thorgeirsson 1996). It has also been suggested that the
contribution of this cell population to the maintenance of liver function is increased
in disease states (Crosby et al. 1998;Libbrecht et al. 2000;Roskams et al. 2003), and
that this "stem cell" population may be the progenitor for the development of HCC,
rather than the mature hepatocyte (Dumble et al. 2002;Sell et al. 1989;Sell 1993). It
has not been determined in the experiments herein whether a significant progenitor
population exists, or ifRb loss has a preferential effect on the expansion of this
population compared to the mature hepatocyte. These would be very interesting
questions to pursue, particularly in light of the stem cell theory of HCC (reviewed
(Roskams 2006).
Role of Rb in a chemical model of carcinogenesis
Having determined a role of Rb in the regulation of liver regeneration and
polyploidisation, a further aim of this thesis was to determine directly what role loss
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of Rb may play on the development of HCC. Returning to the founding premise of
this thesis, that the role of Rb as a regulator of cell cycle progression would be most
obvious when hepatocytes were replicating, we designed a model to recapitulate the
environment of chronic liver disease from which HCC develops. We achieved this
using DEN as a DNA damaging agent, followed by repeated administration of CC14
as a necrotic agent to produce a period of sustained hepatocyte proliferation. Using
AdCre we then imposed on this environment acute Rb loss. Similar methods
involving chemical carcinogenesis have been used to determine the effect of loss of
other tumour suppressor genes on HCC development (Finnberg et al. 2004;Jensen et
al. 2003;Lukas et al. 1999). In these experiments, Rb loss was associated with a
distinct phenotype characterised by a number of histological changes in the liver,
including the increased prevalence ofmitotic figures, apoptotic bodies, and, most
strikingly, the accelerated development of foci of preneoplastic hepatocytes. These
foci were larger and more frequent in Rb deleted mice than in controls, and
represented a significantly higher proportion of the liver cross sectional area. These
preneoplastic foci were shown to have higher proliferative indices than surrounding
tissue, and thus represent hyperplastic cell populations. Hyperplastic foci represent
pre-malignant clones, and the frequency of such foci in human liver has been
positively correlated with the multiplicity ofHCA (Sugitani et al. 1998). Thus, loss
of the regulatory function of pRb appears to accelerate the preneoplastic phase of
hepatocarcinogenesis. These changes were demonstrable after the relatively short
period ofpromotion of only 6 weeks.
The observations that Rb loss could be demonstrated in laser captured liver
preneoplastic foci and in surrounding normal tissue, and that preneoplastic foci also
occurred in control mice, demonstrates that Rb loss is not required for foci
development in this model. DEN treatment causes indiscriminate DNA damage, and
it is probable that the larger, more frequent foci demonstrated following AdCre
treatment harbour additional mutations as well as loss of Rb. Together these
observations make it unlikely that Rb loss alone is sufficient to initiate the
development ofHCC. The larger fraction of preneoplastic foci in AdCre treated
animals clearly demonstrates Rb loss has a significant effect on the expansion of this
137
preneoplastic cell type, presumably through deregulated proliferation, and possibly
through increased genomic instability, as discussed earlier. It would be of interest to
further characterise these foci, looking in particular for further mutations, such as
that of p53.
The experimental protocol for these carcinogenesis experiments was necessarily
short so that the additive effect ofp53 loss in addition to that of Rb could be
assessed. It would obviously be of interest to repeat these experiments using a much
longer protocol to determine whether the effect of Rb loss was associated with an
actual increased tumour burden compared to controls.
The pattern of preneoplastic development in these livers was typical of previous
descriptions of DEN-induced carcinogenesis, with foci made up of small diploid
cells (Sell 1993;Vesselinovitch et al. 1978;Vesselinovitch et al. 1983). The shift
between a polyploidizing growth pattern to a mitotic one is characteristic of
hepatocarcinogenesis (Schwarze et al. 1984a), and it is attractive to hypothesise that
the loss ofpolyploidisation seen in these regeneration experiments following Rb loss
may play a role in switching between growth patterns consequently seen in the
carcinogenesis model.
Intriguingly, there is also the possibility that the lineage of these foci of diploid cells
is not that of the mature hepatocyte but that of a liver progenitor. The lineage of
hepatocellular carcinoma remains undetermined and, as mentioned above, different
animal models have suggested different candidates for the origin ofHCC. As
discussed in the second section of this discussion, the preferential expansion of a
progenitor lineage could explain the emergence of a diploid population seen
following regeneration. Whether clonal expansion could occur from this population
to produce preneoplastic foci has not been determined, but it would be of interest to
examine these foci more closely in an attempt to determine their lineage.
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In terms of the relevance of these results to the development of HCC in the human,
it has been demonstrated recently that the pattern of gene expression which occurs in
murine liver tumours following DEN is similar to that of clinically aggressive human
HCCs (Lee et al. 2004;Lee et al. 2005). This suggests the effect we demonstrate in
these experiments of Rb loss in a model ofDEN initiation, may be directly indicative
of the potential effect of Rb loss in human tumours. Nevertheless, it would be of
interest to determine the role of Rb in alternative non toxic models ofHCC, such as
the HBx transgenic mouse.
Increased apoptosis following Rb loss in a chemical model of
carcinogenesis
Rb deletion in combination with a period of sustained liver damage in the
carcinogenesis model induced higher levels of apoptosis in these experiments.
Increased rates of apoptosis in parallel with accelerated development of preneoplastic
foci have been demonstrated in human liver during the development of HCC (Park et
al. 2001). Increased apoptosis has been shown to have a negative correlation with
prognosis of HCC (Ito et al. 1999b). Elevated levels of apoptosis may be a
consequence of the changes in the liver architecture that occur during the
development of preneoplastic foci (Grasl-Kraupp et al. 1997). However, in our
model, increased rates of apoptosis may be a result of Rb loss. Apoptosis is a
characteristic feature of Rb loss in a number of different systems (Almasan et al.
1995;Clarke et al. 1992) and is believed to be mediated via p53 dependent and
independent mechanisms leading to increased E2F activity. (Tsai et al. 1998).
Increased apoptosis following loss of pRb appears to contradict the role of pRb as a
tumour suppressor, and it has been suggested that loss ofmultiple apoptotic
pathways must occur concomitantly for loss of pRb to be a significant event in
oncogenesis (Sherr et al. 2002).
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Loss ofp53 in addition to that ofRb produces a characteristic
phenotype
To determine whether there was a synergism between p53 loss and Rb loss in the
development of HCC, the carcinogenesis model was repeated using p53 null mice
that were treated with AdCre. The additional loss ofRb produced a phenotype which
could be clearly distinguished from that due to Rb loss alone, with features of
additional increased cell turnover, multiple abnormal mitoses, gross pleomorphism
and a shift from foci of hyperplastic cells to a more diffuse pattern of abnormalities.
Concurrent alterations in both p53 and Rb pathways have been demonstrated in a
significant proportion of human HCCs, and tend to be more common in poorly
differentiated tumours. (Edamoto et al. 2003).
Final Conclusion
In summary, the development of a liver specific conditional knockout has allowed a
demonstration that loss of Rb deregulates the normally tightly controlled process of
hepatocyte proliferation which occurs during liver regeneration. In addition Rb loss
brings about a switch in the growth pattern of hepatocytes following regeneration
with a loss of polyploidisation and the emergence of a diploid cell population.
Deregulation of these two processes would be expected to contribute to
hepatocarcinogenesis which has been demonstrated directly through a model of
promotion of hepatocyte regeneration following Rb loss which accelerated the
development of premalignant changes in the liver. These findings suggest Rb loss
may be a critical event in the development of liver cancer.
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Appendix





Dissolved in 800ml dH20
pH adjusted to 7.6 and made up to 1 litre.
Stock Solution pH7.6
2g Trisodium Citrate (Sigma)
121mg Tris (Sigma)
1.044 Spermine tetrahydrochloride (Sigma)
2ml NonidetP40 (Sigma)
Dissolved in 1.8L dH20
pH adjusted to 7.6 and made up to 2 Litres with dH20
Vindelov A, pH 7.6
500ml Stock Solution
15mg Trypsin (Sigma)
(stored at -20°C and brought to room temperature)
Vindelov B, pH 7.6
500ml Stock Solution
250mg Trypsin Inhibitor (Sigma)
50mg RNaseA (Sigma)
(stored at -20°C and brought to room temperature)




(stored at -20°C and brought to room temperature, protected at all times from direct light
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